{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T23:39:38Z","timestamp":1793662778356,"version":"4.5.1"},"reference-count":568,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"University of Salamanca"},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["FIS PI13\/02846"],"award-info":[{"award-number":["FIS PI13\/02846"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["RTICC RD12\/0036\/0001"],"award-info":[{"award-number":["RTICC RD12\/0036\/0001"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"name":"JCyL","award":["SA181U13"],"award-info":[{"award-number":["SA181U13"]}]},{"name":"Fundaci\u00f3n en Memoria de D. Samuel Sol\u00f3rzano Barruso","award":["FS\/25-2014"],"award-info":[{"award-number":["FS\/25-2014"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.ejpb.2015.03.018","type":"journal-article","created":{"date-parts":[[2015,4,2]],"date-time":"2015-04-02T23:46:26Z","timestamp":1428018386000},"page":"52-79","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1702,"special_numbering":"C","title":["Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy"],"prefix":"10.1016","volume":"93","author":[{"given":"Edgar","family":"P\u00e9rez-Herrero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Fern\u00e1ndez-Medarde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2015.03.018_b0005","unstructured":"What You Need to Know About Cancer, National Cancer Institute, U.S. Department of Health and Human Services, 2006."},{"key":"10.1016\/j.ejpb.2015.03.018_b0010","series-title":"Cell Cycle and Growth Control: Biomolecular Regulation and Cancer","author":"Stein","year":"2004"},{"key":"10.1016\/j.ejpb.2015.03.018_b0015","series-title":"The Biological Basis of Cancer","author":"McKinnell","year":"1998"},{"key":"10.1016\/j.ejpb.2015.03.018_b0020","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/417906a","article-title":"Cancer: lucky draw in the gene raffle","volume":"417","author":"Pollock","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.ejpb.2015.03.018_b0025","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.ejpb.2015.03.018_b0030","series-title":"Clinical Oncology","article-title":"Progressing from gene mutations to cancer","author":"Fearon","year":"2008"},{"key":"10.1016\/j.ejpb.2015.03.018_b0035","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1056\/NEJMra072367","article-title":"Oncogenes and cancer","volume":"358","author":"Croce","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejpb.2015.03.018_b0040","doi-asserted-by":"crossref","first-page":"3475","DOI":"10.1038\/sj.onc.1205322","article-title":"Tumor suppressor genes in normal and malignant hematopoiesis","volume":"21","author":"Krug","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.ejpb.2015.03.018_b0045","series-title":"Holland-Frei Cancer Medicine","first-page":"86","article-title":"Tumor-suppressor genes","author":"Park","year":"2003"},{"key":"10.1016\/j.ejpb.2015.03.018_b0050","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/nrc1529","article-title":"Timeline: chemotherapy and the war on cancer","volume":"5","author":"Chabner","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejpb.2015.03.018_b0055","first-page":"391","article-title":"Origins of cancer therapy","volume":"74","author":"Papac","year":"2001","journal-title":"Yale J. Biol. Med."},{"key":"10.1016\/j.ejpb.2015.03.018_b0060","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1056\/NEJM195807102590204","article-title":"Therapy of choriocarcinoma and related trophoblastic tumors with folic acid and purine antagonists","volume":"259","author":"Li","year":"1958","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejpb.2015.03.018_b0065","doi-asserted-by":"crossref","first-page":"881","DOI":"10.7326\/0003-4819-73-6-881","article-title":"Combination chemotherapy in the treatment of advanced Hodgkin\u2019s disease","volume":"73","author":"Devita","year":"1970","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ejpb.2015.03.018_b0070","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJM197411072911902","article-title":"Adjuvant methotrexate and citrovorum-factor treatment of osteogenic sarcoma","volume":"291","author":"Jaffe","year":"1974","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejpb.2015.03.018_b0075","first-page":"537","article-title":"Designing platinum compounds in cancer: structures and mechanisms","volume":"5","author":"Boulikas","year":"2007","journal-title":"Cancer Therapy"},{"key":"10.1016\/j.ejpb.2015.03.018_b0080","series-title":"The Story of Taxol: Nature and Politics in the Pursuit of an Anti-cancer Drug","author":"Goodman","year":"2001"},{"key":"10.1016\/j.ejpb.2015.03.018_b0085","unstructured":"Centerwatch, FDA Approved Drugs by Therapeutic Area \u2013 Oncology."},{"key":"10.1016\/j.ejpb.2015.03.018_b0090","unstructured":"Clinical Trials."},{"key":"10.1016\/j.ejpb.2015.03.018_b0095","unstructured":"Hematology\/Oncology (Cancer) Approvals & Safety Notifications, U.S. Food Drug Administration (FDA), U.S. Department of Health and Human Services, 2015."},{"key":"10.1016\/j.ejpb.2015.03.018_b0100","first-page":"57","article-title":"Targeted therapy for cancer","volume":"2","author":"Wu","year":"2006","journal-title":"J. Cancer Mol."},{"key":"10.1016\/j.ejpb.2015.03.018_b0105","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/nrd3270","article-title":"Antibody\u2013drug conjugates for cancer: poised to deliver?","volume":"9","author":"Hughes","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejpb.2015.03.018_b0110","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/nrc903","article-title":"Ligand-targeted therapeutics in anticancer therapy","volume":"2","author":"Allen","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejpb.2015.03.018_b0115","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ctrv.2007.07.017","article-title":"Peptide-based radiopharmaceuticals and cytotoxic conjugates: potential tools against cancer","volume":"34","author":"Okarvi","year":"2008","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.ejpb.2015.03.018_b0120","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jconrel.2010.08.027","article-title":"To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery","volume":"148","author":"Danhier","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2015.03.018_b0125","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/nrc3236","article-title":"Antibody therapy of cancer","volume":"12","author":"Scott","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejpb.2015.03.018_b0130","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(09)60251-8","article-title":"Monoclonal antibodies for cancer immunotherapy","volume":"373","author":"Weiner","year":"2009","journal-title":"The Lancet"},{"key":"10.1016\/j.ejpb.2015.03.018_b0135","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1073\/pnas.232686499","article-title":"A monoclonal antibody recognizing human cancers with amplification\/overexpression of the human epidermal growth factor receptor","volume":"100","author":"Jungbluth","year":"2003","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ejpb.2015.03.018_b0140","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1046\/j.1523-5394.1998.006003195.x","article-title":"Rituximab: a new therapeutic monoclonal antibody for non-Hodgkin\u2019s lymphoma","volume":"6","author":"Scott","year":"1998","journal-title":"Cancer Pract."},{"key":"10.1016\/j.ejpb.2015.03.018_b0145","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1367-5931(99)80067-2","article-title":"The development and therapeutic potential of protein kinase inhibitors","volume":"3","author":"Cohen","year":"1999","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.ejpb.2015.03.018_b0150","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejpb.2015.03.018_b0155","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nrd839","article-title":"Glivec (STI571, Imatinib), a rationally developed, targeted anticancer drug","volume":"1","author":"Capdeville","year":"2002","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejpb.2015.03.018_b0160","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1001\/jama.290.16.2149","article-title":"Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial","volume":"290","author":"Kris","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.ejpb.2015.03.018_b0165","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1517\/14712598.1.2.253","article-title":"General aspects of anti-angiogenesis and cancer therapy","volume":"1","author":"Zogakis","year":"2001","journal-title":"Expert Opin. Biol. Therapy"},{"key":"10.1016\/j.ejpb.2015.03.018_b0170","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/nrd1957","article-title":"Antibody targeted drugs as cancer therapeutics","volume":"5","author":"Schrama","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejpb.2015.03.018_b0175","doi-asserted-by":"crossref","first-page":"13695","DOI":"10.1073\/pnas.1314120110","article-title":"Antibody\u2013drug conjugates","volume":"110","author":"Ornes","year":"2013","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ejpb.2015.03.018_b0180","first-page":"1490","article-title":"Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia","volume":"7","author":"Bross","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejpb.2015.03.018_b0185","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/1097-0142(20010715)92:2<406::AID-CNCR1336>3.0.CO;2-U","article-title":"Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation","volume":"92","author":"Giles","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.ejpb.2015.03.018_b0190","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1182\/blood-2003-01-0255","article-title":"Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation","volume":"102","author":"Wadleigh","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ejpb.2015.03.018_b0195","doi-asserted-by":"crossref","first-page":"4838","DOI":"10.1182\/blood-2013-03-490482","article-title":"Gemtuzumab ozogamicin in acute myeloid leukemia: a remarkable saga about an active drug","volume":"121","author":"Rowe","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ejpb.2015.03.018_b0200","doi-asserted-by":"crossref","first-page":"475","DOI":"10.2217\/imt.11.15","article-title":"Brentuximab vedotin for the treatment of CD30+ lymphomas","volume":"3","author":"Foyil","year":"2011","journal-title":"Immunotherapy"},{"key":"10.1016\/j.ejpb.2015.03.018_b0205","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1517\/13543784.2011.641532","article-title":"Brentuximab vedotin (SGN-35), an antibody\u2013drug conjugate for the treatment of CD30-positive malignancies","volume":"21","author":"Gualberto","year":"2012","journal-title":"Expert Opin. Invest. Drugs"},{"key":"10.1016\/j.ejpb.2015.03.018_b0210","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejpb.2015.03.018_b0215","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1185\/03007995.2013.775113","article-title":"Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer","volume":"29","author":"Boyraz","year":"2013","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.ejpb.2015.03.018_b0220","first-page":"248","article-title":"Glembatumumab vedotin, a conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer","volume":"12","author":"Naumovski","year":"2010","journal-title":"Curr. Opin. Mol. Ther."},{"key":"10.1016\/j.ejpb.2015.03.018_b0225","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/sj.bjc.6605816","article-title":"Targeting pancreatic and ovarian carcinomas using the auristatin-based anti-CD70 antibody-drug conjugate SGN-75","volume":"103","author":"Ryan","year":"2010","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejpb.2015.03.018_b0230","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1124\/jpet.109.155549","article-title":"The pharmacologic basis for antibody-auristatin conjugate activity","volume":"330","author":"Alley","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejpb.2015.03.018_b0235","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/cbdd.12085","article-title":"Antibody-drug conjugates for the treatment of cancer","volume":"81","author":"Flygare","year":"2013","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.ejpb.2015.03.018_b0240","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-62703-541-5_1","article-title":"Antibody-drug conjugate (ADC) clinical pipeline: a review","author":"Sassoon","year":"2013","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ejpb.2015.03.018_b0245","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1073\/pnas.1011379108","article-title":"Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo","volume":"108","author":"Dhar","year":"2011","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ejpb.2015.03.018_b0250","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1021\/mp200007b","article-title":"Development of a peptide-drug conjugate for prostate cancer therapy","volume":"8","author":"Tai","year":"2011","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2015.03.018_b0255","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1182\/blood-2010-05-282921","article-title":"Targeting neuropilin-1 in human leukemia and lymphoma","volume":"117","author":"Karjalainen","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ejpb.2015.03.018_b0260","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2174\/156720111793663598","article-title":"Use of analogs of peptide hormones conjugated to cytotoxic radicals for chemotherapy targeted to receptors on tumors","volume":"8","author":"Schally","year":"2011","journal-title":"Curr. Drug Deliv."},{"key":"10.1016\/j.ejpb.2015.03.018_b0265","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/med.20225","article-title":"Peptide-mediated targeted drug delivery","volume":"32","author":"Majumdar","year":"2012","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejpb.2015.03.018_b0270","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1158\/1535-7163.MCT-11-0566","article-title":"Safety, pharmacokinetics, and activity of GRN1005, a novel conjugate of angiopep-2, a peptide facilitating brain penetration, and paclitaxel, in patients with advanced solid tumors","volume":"11","author":"Kurzrock","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ejpb.2015.03.018_b0275","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1021\/bc9002019","article-title":"Antibody\u2013drug conjugates: linking cytotoxic payloads to monoclonal antibodies","volume":"21","author":"Ducry","year":"2009","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ejpb.2015.03.018_b0280","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1756-8722-5-70","article-title":"Targeted drug delivery for cancer therapy: the other side of antibodies","volume":"5","author":"Firer","year":"2012","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejpb.2015.03.018_b0285","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/j.1552-4604.1996.tb04152.x","article-title":"Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi\u2019s sarcoma","volume":"36","author":"Northfelt","year":"1996","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejpb.2015.03.018_b0290","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.drudis.2006.07.005","article-title":"Exploiting the enhanced permeability and retention effect for tumor targeting","volume":"11","author":"Iyer","year":"2006","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejpb.2015.03.018_b0295","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/nrd2614","article-title":"Nanoparticle therapeutics: an emerging treatment modality for cancer","volume":"7","author":"Davis","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejpb.2015.03.018_b0300","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/nnano.2007.387","article-title":"Nanocarriers as an emerging platform for cancer therapy","volume":"2","author":"Peer","year":"2007","journal-title":"Nat. Nano"},{"key":"10.1016\/j.ejpb.2015.03.018_b0305","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0065-2571(00)00013-3","article-title":"The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting","volume":"41","author":"Maeda","year":"2001","journal-title":"Adv. Enzyme Regul."},{"key":"10.1016\/j.ejpb.2015.03.018_b0310","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.addr.2010.04.009","article-title":"The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect","volume":"63","author":"Fang","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2015.03.018_b0315","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/138955711793564024","article-title":"Drug targeting strategies in cancer treatment: an overview","volume":"11","author":"Arias","year":"2011","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.ejpb.2015.03.018_b0320","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0031-6997(24)01494-7","article-title":"Long-circulating and target-specific nanoparticles: theory to practice","volume":"53","author":"Moghimi","year":"2001","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ejpb.2015.03.018_b0325","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1021\/bc100070g","article-title":"Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects","volume":"21","author":"Maeda","year":"2010","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ejpb.2015.03.018_b0330","first-page":"3752","article-title":"Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size","volume":"55","author":"Yuan","year":"1995","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejpb.2015.03.018_b0335","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jconrel.2012.04.038","article-title":"Macromolecular therapeutics in cancer treatment: the EPR effect and beyond","volume":"164","author":"Maeda","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2015.03.018_b0340","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.addr.2010.09.003","article-title":"Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects","volume":"63","author":"Maruyama","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2015.03.018_b0345","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ijpharm.2005.10.010","article-title":"Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles","volume":"307","author":"Owens Iii","year":"2006","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2015.03.018_b0350","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1158\/1078-0432.CCR-07-1441","article-title":"Therapeutic nanoparticles for drug delivery in cancer","volume":"14","author":"Cho","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejpb.2015.03.018_b0355","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ijpharm.2004.12.010","article-title":"Poly(ethylene oxide)-modified poly(\u025b-caprolactone) nanoparticles for targeted delivery of tamoxifen in breast cancer","volume":"293","author":"Shenoy","year":"2005","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2015.03.018_b0360","doi-asserted-by":"crossref","first-page":"11613","DOI":"10.1073\/pnas.0801763105","article-title":"The effect of particle design on cellular internalization pathways","volume":"105","author":"Gratton","year":"2008","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ejpb.2015.03.018_b0365","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.chembiol.2006.11.015","article-title":"The binding avidity of a nanoparticle-based multivalent targeted drug delivery platform","volume":"14","author":"Hong","year":"2007","journal-title":"Chem. Biol."},{"key":"10.1016\/j.ejpb.2015.03.018_b0370","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.biomaterials.2012.09.064","article-title":"Intrinsically active nanobody-modified polymeric micelles for tumor-targeted combination therapy","volume":"34","author":"Talelli","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejpb.2015.03.018_b0375","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/S1470-2045(12)70476-X","article-title":"Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study","volume":"13","author":"Mamot","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejpb.2015.03.018_b0380","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1016\/j.ejca.2010.03.019","article-title":"Anti-cancer drug resistance: understanding the mechanisms through the use of integrative genomics and functional RNA interference","volume":"46","author":"Tan","year":"2010","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejpb.2015.03.018_b0385","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nrc706","article-title":"Multidrug resistance in cancer: role of ATP-dependent transporters","volume":"2","author":"Gottesman","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejpb.2015.03.018_b0390","first-page":"1949","article-title":"Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump","volume":"6","author":"Goren","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejpb.2015.03.018_b0395","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0168-3659(01)00460-6","article-title":"Possibility of the reversal of multidrug resistance and the avoidance of side effects by liposomes modified with MRK-16, a monoclonal antibody to P-glycoprotein","volume":"77","author":"Matsuo","year":"2001","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2015.03.018_b0400","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jconrel.2009.01.021","article-title":"Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance","volume":"136","author":"Patil","year":"2009","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2015.03.018_b0405","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0168-3659(01)00309-1","article-title":"Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS","volume":"74","author":"Maeda","year":"2001","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2015.03.018_b0410","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0378-5173(96)04674-1","article-title":"Direct measurement of the extravasation of polyethyleneglycol-coated liposomes into solid tumor tissue by in vivo fluorescence microscopy","volume":"144","author":"Unezaki","year":"1996","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2015.03.018_b0415","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/scientificamerican0794-58","article-title":"Barriers to drug delivery in solid tumors","volume":"271","author":"Jain","year":"1994","journal-title":"Sci. Am."},{"key":"10.1016\/j.ejpb.2015.03.018_b0420","doi-asserted-by":"crossref","first-page":"6732","DOI":"10.1158\/0008-5472.CAN-05-4199","article-title":"Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models","volume":"66","author":"Kirpotin","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejpb.2015.03.018_b0425","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jconrel.2011.09.063","article-title":"Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress","volume":"161","author":"Lammers","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2015.03.018_b0430","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/nrclinonc.2010.139","article-title":"Delivering nanomedicine to solid tumors","volume":"7","author":"Jain","year":"2010","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"2010","key":"10.1016\/j.ejpb.2015.03.018_b0435","first-page":"2926","article-title":"The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma","volume":"46","author":"Johannsen","year":"1990","journal-title":"Eur. J. Cancer (Oxford, England)"},{"key":"10.1016\/j.ejpb.2015.03.018_b0440","doi-asserted-by":"crossref","first-page":"5277","DOI":"10.1158\/1078-0432.CCR-10-0791","article-title":"A phase I study of a tropism-modified conditionally replicative adenovirus for recurrent malignant gynecologic diseases","volume":"16","author":"Kimball","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejpb.2015.03.018_b0445","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1158\/1078-0432.CCR-09-3167","article-title":"Oncolytic adenovirus ICOVIR-7 in patients with advanced and refractory solid tumors","volume":"16","author":"Nokisalmi","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejpb.2015.03.018_b0450","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1073\/pnas.0914140107","article-title":"Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles","volume":"107","author":"Choi","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejpb.2015.03.018_b0455","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1021\/nn900002m","article-title":"Impact of nanotechnology on drug delivery","volume":"3","author":"Farokhzad","year":"2009","journal-title":"ACS Nano"},{"key":"10.1016\/j.ejpb.2015.03.018_b0460","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/sj.clpt.6100400","article-title":"Nanoparticles in medicine: therapeutic applications and developments","volume":"83","author":"Zhang","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejpb.2015.03.018_b0465","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/nrc1958","article-title":"Polymer conjugates as anticancer nanomedicines","volume":"6","author":"Duncan","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejpb.2015.03.018_b0470","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/nrd1088","article-title":"The dawning era of polymer therapeutics","volume":"2","author":"Duncan","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejpb.2015.03.018_b0475","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.addr.2010.12.005","article-title":"Prodrug-based intracellular delivery of anticancer agents","volume":"63","author":"Bildstein","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2015.03.018_b0480","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.carbpol.2012.10.036","article-title":"A review of polysaccharide cytotoxic drug conjugates for cancer therapy","volume":"92","author":"Goodarzi","year":"2013","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.ejpb.2015.03.018_b0485","first-page":"1665","article-title":"Phase II study of YM881 (zinostatin stimalamer) suspension injected into the hepatic artery. Research Group for Intra-arterial Injection Therapy with YM881","volume":"18","author":"Taguchi","year":"1991","journal-title":"Gan To Kagaku Ryoho"},{"key":"10.1016\/j.ejpb.2015.03.018_b0490","doi-asserted-by":"crossref","first-page":"715","DOI":"10.2174\/1568011023353679","article-title":"Styrene maleic acid neocarzinostatin treatment for hepatocellular carcinoma","volume":"2","author":"Abe","year":"2002","journal-title":"Curr. Med. Chem. Anticancer Agents"},{"key":"10.1016\/j.ejpb.2015.03.018_b0495","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0090-9556(25)08348-5","article-title":"Clinical pharmacology of polyethylene glycol-l-asparaginase","volume":"14","author":"Ho","year":"1986","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejpb.2015.03.018_b0500","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/0168-3659(90)90127-F","article-title":"The clinical efficacy of poly(ethylene glycol)-modified proteins","volume":"11","author":"Fuertges","year":"1990","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2015.03.018_b0505","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S0169-409X(03)00110-8","article-title":"Pegaspargase: a review of clinical studies","volume":"55","author":"Graham","year":"2003","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2015.03.018_b0510","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1634\/theoncologist.12-8-991","article-title":"FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL)","volume":"12","author":"Dinndorf","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.ejpb.2015.03.018_b0515","first-page":"359","article-title":"First-line treatment of acute lymphoblastic leukemia with pegasparaginase","volume":"3","author":"Masetti","year":"2009","journal-title":"Biologics"},{"key":"10.1016\/j.ejpb.2015.03.018_b0520","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1158\/0008-5472.CAN-06-1945","article-title":"Pegylated recombinant human arginase (rhArg-peg5,000mw) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through arginine depletion","volume":"67","author":"Cheng","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejpb.2015.03.018_b0525","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s10637-012-9807-9","article-title":"A phase 1 dose-escalating study of pegylated recombinant human arginase 1 (Peg-rhArg1) in patients with advanced hepatocellular carcinoma","volume":"31","author":"Yau","year":"2013","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.ejpb.2015.03.018_b0530","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1200\/JCO.2004.11.120","article-title":"Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase I\/II studies","volume":"22","author":"Izzo","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejpb.2015.03.018_b0535","doi-asserted-by":"crossref","first-page":"7660","DOI":"10.1200\/JCO.2005.02.0933","article-title":"Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies","volume":"23","author":"Ascierto","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejpb.2015.03.018_b0540","doi-asserted-by":"crossref","unstructured":"C. Mueller, S. Al-Batran, E. Jaeger, M. Bausch, N. Sethuraman, C. Unger, A phase I trial of PEGylated glutaminase (PEG-PGA) in combination with 6-diazo-5-oxo-l-norleucine (DON) in advanced, refractory, solid tumors, in: 2007 ASCO Annual Meeting Proceedings, 2007 (J. Clin. Oncol.).","DOI":"10.1200\/jco.2008.26.15_suppl.2533"},{"key":"10.1016\/j.ejpb.2015.03.018_b0545","doi-asserted-by":"crossref","unstructured":"C. Mueller, S. Al-Batran, E. Jaeger, B. Schmidt, M. Bausch, N. Sethuraman, C. Unger, N. Setuhuraman, A phase IIa study of PEGylated glutaminase (PEG-PGA) plus 6-diazo-5-oxo-l-norleucine (DON) in patients with advanced refractory solid tumors, in: 2008 ASCO Annual Meeting Proceedings, 2008 (J. Clin. Oncol.).","DOI":"10.1200\/jco.2008.26.15_suppl.2533"},{"key":"10.1016\/j.ejpb.2015.03.018_b0550","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/BF00874158","article-title":"Polyethylene glycol conjugated interleukin-2: clinical and immunologic effects in patients with advanced renal cell carcinoma","volume":"11","author":"Bukowski","year":"1993","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.ejpb.2015.03.018_b0555","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/1097-0142(19950815)76:4<687::AID-CNCR2820760424>3.0.CO;2-M","article-title":"The use of polyethylene glycol-modified interleukin-2 (PEG-IL-2) in the treatment of patients with metastatic renal cell carcinoma and melanoma. A phase I study and a randomized prospective study comparing IL-2 alone versus IL-2 combined with PEG-IL-2","volume":"76","author":"Yang","year":"1995","journal-title":"Cancer"},{"key":"10.1016\/j.ejpb.2015.03.018_b0560","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1046\/j.1524-4725.2000.0260111037.x","article-title":"Effect of perilesional injections of PEG-interleukin-2 on basal cell carcinoma","volume":"26","author":"Kaplan","year":"2000","journal-title":"Dermatol. Surg."},{"key":"10.1016\/j.ejpb.2015.03.018_b0565","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1200\/JCO.2002.02.051","article-title":"Pegylated interferon alfa-2b treatment for patients with solid tumors: a phase I\/II study","volume":"20","author":"Bukowski","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejpb.2015.03.018_b0570","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1097\/CAD.0b013e3282eea391","article-title":"Phase II trial of pegylated interferon and thalidomide in malignant metastatic melanoma","volume":"18","author":"Vaishampayan","year":"2007","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.ejpb.2015.03.018_b0575","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/sj.bjc.6605189","article-title":"Two phase II trials of temozolomide with interferon-[alpha]2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme","volume":"101","author":"Groves","year":"2009","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejpb.2015.03.018_b0580","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1097\/CJI.0b013e3181587977","article-title":"Phase I\/II trial of outpatient PEG-interferon with interleukin-2 in advanced renal cell carcinoma: a cytokine working group study","volume":"30","author":"Clark","year":"2007","journal-title":"J. Immunother."},{"key":"10.1016\/j.ejpb.2015.03.018_b0585","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/sj.leu.2403217","article-title":"Pegylated recombinant interferon alpha-2b vs recombinant interferon alpha-2b for the initial treatment of chronic-phase chronic myelogenous leukemia: a phase III study","volume":"18","author":"Michallet","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.ejpb.2015.03.018_b0590","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(08)61033-8","article-title":"Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial","volume":"372","author":"Eggermont","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ejpb.2015.03.018_b0595","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1080\/10428190601175393","article-title":"Phase II, randomized, multicenter, comparative study of peginterferon-alpha-2a (40 kD) (Pegasys) versus interferon alpha-2a (Roferon-A) in patients with treatment-naive, chronic-phase chronic myelogenous leukemia","volume":"48","author":"Lipton","year":"2007","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.ejpb.2015.03.018_b0600","doi-asserted-by":"crossref","first-page":"7113","DOI":"10.1158\/1078-0432.CCR-07-1550","article-title":"Phase I evaluation of CDP791, a PEGylated di-Fab\u2019 conjugate that binds vascular endothelial growth factor receptor 2","volume":"13","author":"Ton","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejpb.2015.03.018_b0605","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.addr.2009.02.010","article-title":"PEG conjugates in clinical development or use as anticancer agents: an overview","volume":"61","author":"Pasut","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2015.03.018_b0610","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0169-409X(02)00021-2","article-title":"The origin of pegnology","volume":"54","author":"Davis","year":"2002","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2015.03.018_b0615","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nrd1033","article-title":"Effect of pegylation on pharmaceuticals","volume":"2","author":"Harris","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejpb.2015.03.018_b0620","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1517\/13543776.14.6.859","article-title":"Protein, peptide and non-peptide drug PEGylation for therapeutic application","volume":"14","author":"Pasut","year":"2004","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejpb.2015.03.018_b0625","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1002\/anie.200502113","article-title":"Polymer therapeutics: concepts and applications","volume":"45","author":"Haag","year":"2006","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejpb.2015.03.018_b0630","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1021\/mp200394t","article-title":"Nanomedicine(s) under the microscope","volume":"8","author":"Duncan","year":"2011","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2015.03.018_b0635","first-page":"7","article-title":"Poly(ethylene glycol)-prodrug conjugates: concept, design, and applications","volume":"103973","author":"Banerjee","year":"2012","journal-title":"J. Drug Deliv."},{"key":"10.1016\/j.ejpb.2015.03.018_b0640","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1039\/c1py00034a","article-title":"FDA-approved poly(ethylene glycol)-protein conjugate drugs","volume":"2","author":"Alconcel","year":"2011","journal-title":"Polym. Chem."},{"key":"10.1016\/j.ejpb.2015.03.018_b0645","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.addr.2012.08.012","article-title":"Polymer therapeutics-prospects for 21st century: the end of the beginning","volume":"65","author":"Duncan","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2015.03.018_b0650","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.copbio.2011.06.003","article-title":"Polymer\u2013drug conjugates as nano-sized medicines","volume":"22","author":"Canal","year":"2011","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.ejpb.2015.03.018_b0655","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0169-409X(02)00028-5","article-title":"Use of peginterferon alfa-2a (40 KD) (Pegasys\u00ae) for the treatment of hepatitis C","volume":"54","author":"Rajender Reddy","year":"2002","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2015.03.018_b0660","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/nrd3349","article-title":"Pegloticase","volume":"10","author":"Schlesinger","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejpb.2015.03.018_b0665","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1056\/NEJM200004203421604","article-title":"Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant","volume":"342","author":"Trainer","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejpb.2015.03.018_b0670","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1016\/S0140-6736(01)06844-1","article-title":"Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist","volume":"358","author":"van der Lely","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.ejpb.2015.03.018_b0675","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/S0169-409X(03)00111-X","article-title":"Pegvisomant in the treatment of acromegaly","volume":"55","author":"Parkinson","year":"2003","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2015.03.018_b0680","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.2174\/1381612043452613","article-title":"The design and development of pegfilgrastim (PEG-rmetHuG-CSF, Neulasta)","volume":"10","author":"Molineux","year":"2004","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.ejpb.2015.03.018_b0685","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1200\/JCO.2005.09.102","article-title":"First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study","volume":"23","author":"Vogel","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejpb.2015.03.018_b0690","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/annonc\/mdg019","article-title":"A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy","volume":"14","author":"Green","year":"2003","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejpb.2015.03.018_b0695","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.cgh.2010.04.021","article-title":"Certolizumab pegol in patients with moderate to severe Crohn\u2019s disease and secondary failure to infliximab","volume":"8","author":"Sandborn","year":"2010","journal-title":"Clin. Gastroenterol. Hepatol.: Off. Clin. Pract. J. Am. Gastroenterol. Assoc."},{"key":"10.1016\/j.ejpb.2015.03.018_b0700","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S0140-6736(06)69120-4","article-title":"Novel strategies for stimulating erythropoiesis and potential new treatments for anaemia","volume":"368","author":"Macdougall","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.ejpb.2015.03.018_b0705","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1136\/bjo.2007.128942","article-title":"Combined pegaptanib sodium (macugen) and photodynamic therapy in predominantly classic juxtafoveal choroidal neovascularisation in age related macular degeneration","volume":"92","author":"Calvo-Gonzalez","year":"2008","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.ejpb.2015.03.018_b0710","first-page":"353","article-title":"Pegaptanib (macugen): treating neovascular age-related macular degeneration and current role in clinical practice","volume":"19","author":"Vavvas","year":"2006","journal-title":"Ophthalmol. Clin. N. Am."},{"key":"10.1016\/j.ejpb.2015.03.018_b0715","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/IAE.0b013e318261a73c","article-title":"Intravitreal pegaptanib sodium (macugen) for treatment of myopic choroidal neovascularization: a morphologic and functional study","volume":"33","author":"Rinaldi","year":"2013","journal-title":"Retina"},{"key":"10.1016\/j.ejpb.2015.03.018_b0720","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s12094-012-0766-6","article-title":"Nanoparticle delivery systems for cancer therapy: advances in clinical and preclinical research","volume":"14","author":"Egusquiaguirre","year":"2012","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.ejpb.2015.03.018_b0725","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1158\/1078-0432.CCR-03-0315","article-title":"A phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors","volume":"10","author":"Rademaker-Lakhai","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejpb.2015.03.018_b0730","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.addr.2009.06.004","article-title":"ProLindac\u2122 (AP5346): a review of the development of an HPMA DACH platinum polymer therapeutic","volume":"61","author":"Nowotnik","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2015.03.018_b0735","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.3892\/ijo_00000293","article-title":"Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer","volume":"34","author":"Seymour","year":"2009","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.ejpb.2015.03.018_b0740","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/BF00874153","article-title":"Phase I clinical and pharmacokinetic trial of dextran conjugated doxorubicin (AD-70, DOX-OXD)","volume":"11","author":"Danhauser-Riedl","year":"1993","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.ejpb.2015.03.018_b0745","doi-asserted-by":"crossref","first-page":"5855","DOI":"10.1158\/1078-0432.CCR-06-2821","article-title":"Phase I trial of poly-l-glutamate camptothecin (CT-2106) administered weekly in patients with advanced solid malignancies","volume":"13","author":"Homsi","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejpb.2015.03.018_b0750","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/sj.bjc.6601922","article-title":"Phase I and pharmacokinetic (PK) study of MAG-CPT (PNU 166148): a polymeric derivative of camptothecin (CPT)","volume":"91","author":"Bissett","year":"2004","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejpb.2015.03.018_b0755","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1158\/1078-0432.CCR-04-1758","article-title":"Phase I and pharmacokinetic study of DE-310 in patients with advanced solid tumors","volume":"11","author":"Soepenberg","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejpb.2015.03.018_b0760","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.addr.2009.05.005","article-title":"Design and development of IT-101, a cyclodextrin-containing polymer conjugate of camptothecin","volume":"61","author":"Davis","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2015.03.018_b0765","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.addr.2009.01.007","article-title":"XMT-1001, a novel polymeric camptothecin pro-drug in clinical development for patients with advanced cancer","volume":"61","author":"Yurkovetskiy","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2015.03.018_b0770","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s00280-008-0746-2","article-title":"A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma","volume":"63","author":"Scott","year":"2009","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejpb.2015.03.018_b0775","first-page":"1","article-title":"First-in-human phase 1\/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies","author":"Weiss","year":"2013","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.ejpb.2015.03.018_b0780","doi-asserted-by":"crossref","unstructured":"Z. Guo, J.J. Wheler, A. Naing, S. Mani, S. Goel, M. Mulcahy, F. Gamza, C. Longley, A. Buchbinder, R. Kurzrock, Clinical pharmacokinetics (PK) of EZN-2208, a novel anticancer agent, in patients (pts) with advanced malignancies: a phase I, first-in-human, dose-escalation study, in: 2008 ASCO Annual Meeting Proceedings, American Society of Clinical Oncology, 2008 (J. Clin. Oncol.).","DOI":"10.1200\/jco.2008.26.15_suppl.2556"},{"key":"10.1016\/j.ejpb.2015.03.018_b0785","doi-asserted-by":"crossref","unstructured":"D.D. Von Hoff, G. Jameson, M.J. Borad, L.S. Rosen, J. Utz, S. Dhar, L. Acosta, T. Barker, J. Walling, J.T. Hamm, First phase I trial of NKTR-102 (PEG-irinotecan) reveals early evidence of broad anti-tumor activity in three schedules, in: 20th, EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Elsevier, Amsterdam, 2008 (Eur. J. Cancer).","DOI":"10.1016\/S1359-6349(08)72529-1"},{"key":"10.1016\/j.ejpb.2015.03.018_b0790","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1021\/bc700333s","article-title":"Novel prodrugs of SN38 using multiarm poly(ethylene glycol) linkers","volume":"19","author":"Zhao","year":"2008","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ejpb.2015.03.018_b0795","doi-asserted-by":"crossref","first-page":"7535","DOI":"10.1158\/1078-0432.CCR-08-0438","article-title":"Clinical and pharmacologic study of the novel prodrug delimotecan (MEN 4901\/T-0128) in patients with solid tumors","volume":"14","author":"Veltkamp","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejpb.2015.03.018_b0800","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/00001813-200104000-00003","article-title":"Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel","volume":"12","author":"Meerum Terwogt","year":"2001","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.ejpb.2015.03.018_b0805","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.juro.2010.09.073","article-title":"Paclitaxel-hyaluronic acid for intravesical therapy of Bacillus Calmette-Gu\u00e9rin refractory carcinoma in situ of the bladder: results of a phase I study","volume":"185","author":"Bassi","year":"2011","journal-title":"J. Urol."},{"key":"10.1016\/j.ejpb.2015.03.018_b0810","first-page":"4085","article-title":"Neoadjuvant paclitaxel poliglumex (PPX), cisplatin, and radiation (RT) for esophageal cancer","volume":"28","author":"Ng","year":"2010","journal-title":"Gastrointest. Cancer Res."},{"key":"10.1016\/j.ejpb.2015.03.018_b0815","doi-asserted-by":"crossref","first-page":"4523","DOI":"10.1200\/JCO.2004.12.043","article-title":"Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma","volume":"22","author":"Sabbatini","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejpb.2015.03.018_b0820","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1097\/JTO.0b013e3181753b4b","article-title":"Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naive advanced non-small cell lung cancer","volume":"3","author":"Langer","year":"2008","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ejpb.2015.03.018_b0825","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s10637-006-8221-6","article-title":"Phase II study of MTX-HSA in combination with cisplatin as first line treatment in patients with advanced or metastatic transitional cell carcinoma","volume":"24","author":"Bolling","year":"2006","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.ejpb.2015.03.018_b0830","doi-asserted-by":"crossref","unstructured":"A. Awada, S. Chan, G. Jerusalem, M. Huizing, R. Coleman, A. Mehdi, S. O\u2019Reilly, J. Hamm, T. Patel, A. Hannah, L. Masuoka, A. Garcia, E. Perez, Significant efficacy in a phase 2 study of NKTR-102, a novel polymer conjugate of irinotecan, in patients with pre-treated metastatic breast cancer (MBC), in: Thirty-Third Annual CTRC-AACR San Antonio Breast Cancer Symposium, Cancer Research, American Association for Cancer Research, San Antonio, TX, USA, 2010.","DOI":"10.1158\/0008-5472.SABCS10-P6-11-01"},{"key":"10.1016\/j.ejpb.2015.03.018_b0835","doi-asserted-by":"crossref","unstructured":"I.B. Vergote, J.P. Micha, C.H. Pippitt Jr., G.G. Rao, D.L. Spitz, N. Reed, G.G. Dark, A. Garcia, D.J. Maslyar, G.J. Rustin, Phase II study of NKTR-102 in women with platinum-resistant\/refractory ovarian cancer, in: 2010 ASCO Annual Meeting, ASCO University, 2010 (J. Clin. Oncol.).","DOI":"10.1200\/jco.2010.28.15_suppl.5013"},{"key":"10.1016\/j.ejpb.2015.03.018_b0840","unstructured":"Opaxio by Cell Therapeutics Inc."},{"key":"10.1016\/j.ejpb.2015.03.018_b0845","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/j.addr.2009.05.007","article-title":"Development of HPMA copolymer\u2013anticancer conjugates: clinical experience and lessons learnt","volume":"61","author":"Duncan","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2015.03.018_b0850","series-title":"Polymeric Drug Delivery Systems","first-page":"1","article-title":"N-(2-hydroxypropyl)methacrylamide copolymer conjugates","author":"Duncan","year":"2005"},{"key":"10.1016\/j.ejpb.2015.03.018_b0855","first-page":"83","article-title":"Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents\u2014drug-polymer conjugates","volume":"5","author":"Vasey","year":"1999","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejpb.2015.03.018_b0860","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0939-6411(00)00075-8","article-title":"HPMA copolymer-anticancer drug conjugates: design, activity, and mechanism of action","volume":"50","author":"Kopecek","year":"2000","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2015.03.018_b0865","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.addr.2009.10.004","article-title":"HPMA copolymers: origins, early developments, present, and future","volume":"62","author":"Kopecek","year":"2010","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2015.03.018_b0870","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.copbio.2011.05.507","article-title":"Polymer therapeutics as nanomedicines: new perspectives","volume":"22","author":"Duncan","year":"2011","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.ejpb.2015.03.018_b0875","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.addr.2009.12.005","article-title":"Do HPMA copolymer conjugates have a future as clinically useful nanomedicines? A critical overview of current status and future opportunities","volume":"62","author":"Duncan","year":"2010","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2015.03.018_b0880","doi-asserted-by":"crossref","first-page":"8","DOI":"10.2174\/157340711795163866","article-title":"CRLX101 (formerly IT-101) \u2013 a novel nanopharmaceutical of camptothecin in clinical development","volume":"7","author":"Young","year":"2011","journal-title":"Curr. Bioact. Compd."},{"key":"10.1016\/j.ejpb.2015.03.018_b0885","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00280-007-0486-8","article-title":"A phase II open-label study of DHA-paclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinoma","volume":"61","author":"Jones","year":"2008","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejpb.2015.03.018_b0890","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1097\/01243894-200611000-00011","article-title":"DHA-paclitaxel (Taxoprexin) as first-line treatment in patients with stage IIIB or IV non-small cell lung cancer: report of a phase II open-label multicenter trial","volume":"1","author":"Payne","year":"2006","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ejpb.2015.03.018_b0895","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s00280-008-0756-0","article-title":"Phase 1 and pharmacokinetic study of weekly docosahexaenoic acid-paclitaxel, Taxoprexin\u00ae, in resistant solid tumor malignancies","volume":"63","author":"Fracasso","year":"2009","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejpb.2015.03.018_b0900","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1093\/annonc\/mdq438","article-title":"Phase 3 study of docosahexaenoic acid-paclitaxel versus dacarbazine in patients with metastatic malignant melanoma","volume":"22","author":"Bedikian","year":"2011","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejpb.2015.03.018_b0905","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.addr.2004.02.003","article-title":"Folate receptor-targeted drugs for cancer and inflammatory diseases","volume":"56","author":"Low","year":"2004","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2015.03.018_b0910","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1200\/JCO.20.6.1668","article-title":"Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin","volume":"20","author":"Seymour","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejpb.2015.03.018_b0915","doi-asserted-by":"crossref","first-page":"3862","DOI":"10.1016\/j.biomaterials.2011.01.073","article-title":"Integrin-assisted drug delivery of nano-scaled polymer therapeutics bearing paclitaxel","volume":"32","author":"Eldar-Boock","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejpb.2015.03.018_b0920","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1371\/journal.pone.0005233","article-title":"Targeting angiogenesis-dependent calcified neoplasms using combined polymer therapeutics","volume":"4","author":"Segal","year":"2009","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ejpb.2015.03.018_b0925","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1002\/anie.200805133","article-title":"Targeting bone metastases with a bispecific anticancer and antiangiogenic polymer\u2013alendronate\u2013taxane conjugate","volume":"48","author":"Miller","year":"2009","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejpb.2015.03.018_b0930","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0168-3659(01)00349-2","article-title":"Water-soluble HPMA copolymer\u2013wortmannin conjugate retains phosphoinositide 3-kinase inhibitory activity in vitro and in vivo","volume":"74","author":"Varticovski","year":"2001","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2015.03.018_b0935","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1007\/s11095-010-0267-7","article-title":"HPMA copolymer-aminohexylgeldanamycin conjugates targeting cell surface expressed GRP78 in prostate cancer","volume":"27","author":"Larson","year":"2010","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2015.03.018_b0940","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1007\/s11095-009-9851-0","article-title":"Targetable HPMA copolymer-aminohexylgeldanamycin conjugates for prostate cancer therapy","volume":"26","author":"Borgman","year":"2009","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2015.03.018_b0945","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jconrel.2007.06.005","article-title":"Intelligent biosynthetic nanobiomaterials for hyperthermic combination chemotherapy and thermal drug targeting of HSP90 inhibitor geldanamycin","volume":"122","author":"Bae","year":"2007","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2015.03.018_b0950","doi-asserted-by":"crossref","first-page":"E200","DOI":"10.1208\/aapsj0902022","article-title":"Polymer-drug conjugates as modulators of cellular apoptosis","volume":"9","author":"Vicent","year":"2007","journal-title":"AAPS J."},{"key":"10.1016\/j.ejpb.2015.03.018_b0955","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1124\/mol.109.054551","article-title":"Polyethylene glycosylated curcumin conjugate inhibits pancreatic cancer cell growth through inactivation of Jab1","volume":"76","author":"Li","year":"2009","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejpb.2015.03.018_b0960","first-page":"333-a","article-title":"Using N-(2-hydroxypropyl)methacrylamide copolymer drug bioconjugate as a novel approach to deliver a Bcl-2-targeting compound HA14-1 in vivo","volume":"2005","author":"Oman","year":"2005","journal-title":"AACR Meet. Abstr."},{"key":"10.1016\/j.ejpb.2015.03.018_b0965","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.addr.2009.06.005","article-title":"Design and development of polymer conjugates as anti-angiogenic agents","volume":"61","author":"Segal","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2015.03.018_b0970","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nm1002","article-title":"Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470","volume":"10","author":"Satchi-Fainaro","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejpb.2015.03.018_b0975","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ccr.2005.02.007","article-title":"Inhibition of vessel permeability by TNP-470 and its polymer conjugate, caplostatin","volume":"7","author":"Satchi-Fainaro","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejpb.2015.03.018_b0980","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/nbt1415","article-title":"An orally delivered small-molecule formulation with antiangiogenic and anticancer activity","volume":"26","author":"Benny","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ejpb.2015.03.018_b0985","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2217\/nnm.13.8","article-title":"Therapeutic nanoparticles in clinics and under clinical evaluation","volume":"8","author":"Sch\u00fctz","year":"2013","journal-title":"Nanomedicine"},{"key":"10.1016\/j.ejpb.2015.03.018_b0990","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/S1359-6446(03)02903-9","article-title":"Nanotech approaches to drug delivery and imaging","volume":"8","author":"Sahoo","year":"2003","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejpb.2015.03.018_b0995","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.tips.2009.08.004","article-title":"Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer","volume":"30","author":"Malam","year":"2009","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejpb.2015.03.018_b1000","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1111\/j.1349-7006.2011.01941.x","article-title":"Nanomedicine in cancer therapy: innovative trends and prospects","volume":"102","author":"Blanco","year":"2011","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ejpb.2015.03.018_b1005","doi-asserted-by":"crossref","first-page":"H1319","DOI":"10.1152\/ajpheart.2000.279.3.H1319","article-title":"Liposome-induced pulmonary hypertension: properties and mechanism of a complement-mediated pseudoallergic reaction","volume":"279","author":"Szebeni","year":"2000","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.ejpb.2015.03.018_b1010","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.tox.2005.07.023","article-title":"Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity","volume":"216","author":"Szebeni","year":"2005","journal-title":"Toxicology"},{"key":"10.1016\/j.ejpb.2015.03.018_b1015","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v18.i6.50","article-title":"Complement activation-related pseudoallergy caused by liposomes, micellar carriers of intravenous drugs, and radiocontrast agents","volume":"18","author":"Szebeni","year":"2001","journal-title":"Crit. Rev. Ther. Drug Carrier Syst."},{"key":"10.1016\/j.ejpb.2015.03.018_b1020","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1080\/10611860701499946","article-title":"Antitumor activity of new liposomal prodrug of mitomycin C in multidrug resistant solid tumor: insights of the mechanism of action","volume":"15","author":"Zalipsky","year":"2007","journal-title":"J. Drug Target."},{"key":"10.1016\/j.ejpb.2015.03.018_b1025","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S0163-7827(03)00033-X","article-title":"Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties","volume":"42","author":"Moghimi","year":"2003","journal-title":"Prog. Lipid Res."},{"key":"10.1016\/j.ejpb.2015.03.018_b1030","first-page":"21","article-title":"The treatment of breast cancer using liposome technology","volume":"212965","author":"Brown","year":"2012","journal-title":"J. Drug Deliv."},{"key":"10.1016\/j.ejpb.2015.03.018_b1035","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s00280-012-1960-5","article-title":"Phase I and pharmacokinetic study of IHL-305 (PEGylated liposomal irinotecan) in patients with advanced solid tumors","volume":"70","author":"Infante","year":"2012","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejpb.2015.03.018_b1040","doi-asserted-by":"crossref","first-page":"7096","DOI":"10.1016\/j.biomaterials.2010.05.045","article-title":"Highly temperature-sensitive liposomes based on a thermosensitive block copolymer for tumor-specific chemotherapy","volume":"31","author":"Kono","year":"2010","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejpb.2015.03.018_b1045","first-page":"105","article-title":"Ultrasound triggered release of cisplatin from liposomes in murine tumors","volume":"137","author":"Shroeder","year":"2009","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2015.03.018_b1050","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.addr.2003.10.038","article-title":"On the formulation of pH-sensitive liposomes with long circulation times","volume":"56","author":"Sim\u00f5es","year":"2004","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2015.03.018_b1055","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/35101072","article-title":"Improving the efficacy of antibody-based cancer therapies","volume":"1","author":"Carter","year":"2001","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejpb.2015.03.018_b1060","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/nrd1632","article-title":"Recent advances with liposomes as pharmaceutical carriers","volume":"4","author":"Torchilin","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejpb.2015.03.018_b1065","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2147\/IJN.S1253","article-title":"Tumor targeting using liposomal antineoplastic drugs","volume":"3","author":"Huwyler","year":"2008","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.ejpb.2015.03.018_b1070","first-page":"39","article-title":"Immunoliposomes for cancer therapy","volume":"8","author":"Kontermann","year":"2006","journal-title":"Curr. Opin. Mol. Ther."},{"key":"10.1016\/j.ejpb.2015.03.018_b1075","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jconrel.2009.08.006","article-title":"Development of a highly stable and targetable nanoliposomal formulation of topotecan","volume":"141","author":"Drummond","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2015.03.018_b1080","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0005-2728(01)00165-7","article-title":"P-nitrophenylcarbonyl-PEG-PE-liposomes: fast and simple attachment of specific ligands, including monoclonal antibodies, to distal ends of PEG chains via p-nitrophenylcarbonyl groups","volume":"1511","author":"Torchilin","year":"2001","journal-title":"Biochim. Biophys. Acta (BBA) \u2013 Biomembr."},{"key":"10.1016\/j.ejpb.2015.03.018_b1085","doi-asserted-by":"crossref","first-page":"E128","DOI":"10.1208\/aapsj0902015","article-title":"Targeted pharmaceutical nanocarriers for cancer therapy and imaging","volume":"9","author":"Torchilin","year":"2007","journal-title":"AAPS J."},{"key":"10.1016\/j.ejpb.2015.03.018_b1090","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ajps.2013.07.010","article-title":"Development of liposomal formulations: from concept to clinical investigations","volume":"8","author":"Fan","year":"2013","journal-title":"Asian J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2015.03.018_b1095","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1200\/JCO.1998.16.7.2445","article-title":"Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi\u2019s sarcoma: results of a randomized phase III clinical trial","volume":"16","author":"Northfelt","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejpb.2015.03.018_b1100","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s00280-012-2042-4","article-title":"Marqibo\u00ae (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine","volume":"71","author":"Silverman","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejpb.2015.03.018_b1105","first-page":"581363","article-title":"Lipoplatin formulation review article","author":"Stathopoulos","year":"2012","journal-title":"J. Drug Deliv."},{"key":"10.1016\/j.ejpb.2015.03.018_b1110","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1007\/s10637-010-9494-3","article-title":"Cellular uptake and cytoplasm\/DNA distribution of cisplatin and oxaliplatin and their liposomal formulation in human colorectal cancer cell HCT116","volume":"29","author":"Tippayamontri","year":"2011","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.ejpb.2015.03.018_b1115","first-page":"4395","article-title":"Synergism in concomitant chemoradiotherapy of cisplatin and oxaliplatin and their liposomal formulation in the human colorectal cancer HCT116 model","volume":"32","author":"Tippayamontri","year":"2012","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ejpb.2015.03.018_b1120","first-page":"3309","article-title":"Application of liposomal technologies for delivery of platinum analogs in oncology","volume":"8","author":"Liu","year":"2013","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.ejpb.2015.03.018_b1125","first-page":"3005","article-title":"Efficacy of cisplatin and lipoplatin in combined treatment with radiation of a colorectal tumor in nude mouse","volume":"33","author":"Tippayamontri","year":"2013","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ejpb.2015.03.018_b1130","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1517\/17425247.2013.778240","article-title":"Liposomes, a promising strategy for clinical application of platinum derivatives","volume":"10","author":"Zalba","year":"2013","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ejpb.2015.03.018_b1135","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1517\/14656566.2011.543129","article-title":"Mifamurtide for the treatment of nonmetastatic osteosarcoma","volume":"12","author":"Ando","year":"2011","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.ejpb.2015.03.018_b1140","article-title":"Osteosarcoma treatment \u2013 where do we stand? A state of the art review","volume":"27","author":"Luetke","year":"2013","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.ejpb.2015.03.018_b1145","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2165\/11204910-000000000-00000","article-title":"Mifamurtide: a review of its use in the treatment of osteosarcoma","volume":"12","author":"Frampton","year":"2010","journal-title":"Paediatr. Drugs"},{"key":"10.1016\/j.ejpb.2015.03.018_b1150","first-page":"9","article-title":"Characterization of 9-nitrocamptothecin liposomes: anticancer properties and mechanisms on hepatocellular carcinoma in vitro and in vivo","volume":"6","author":"Zheng","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ejpb.2015.03.018_b1155","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1634\/theoncologist.2007-0180","article-title":"Concept and clinical evaluation of carrier-mediated anticancer agents","volume":"13","author":"Zamboni","year":"2008","journal-title":"Oncologist"},{"key":"10.1016\/j.ejpb.2015.03.018_b1160","first-page":"541","article-title":"Phase II study of liposomal cisplatin (SPI-77) in platinum-sensitive recurrences of ovarian cancer","volume":"30","author":"Seetharamu","year":"2010","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ejpb.2015.03.018_b1165","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/sj.bjc.6603345","article-title":"Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancer","volume":"95","author":"White","year":"2006","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejpb.2015.03.018_b1170","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1023\/A:1011199028318","article-title":"Phase I-II study of pegylated liposomal cisplatin (SPI-077) in patients with inoperable head and neck cancer","volume":"12","author":"Harrington","year":"2001","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejpb.2015.03.018_b1175","first-page":"1489","article-title":"Liposomal oxaliplatin in the treatment of advanced cancer: a phase I study","volume":"26","author":"Stathopoulos","year":"2006","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ejpb.2015.03.018_b1180","first-page":"1043","article-title":"Current trends of nanotechnology for cancer therapy","volume":"3","author":"Anajwala","year":"2010","journal-title":"Int. J. Pharm. Sci. Nanotechnol."},{"key":"10.1016\/j.ejpb.2015.03.018_b1185","first-page":"689","article-title":"Novel applications of nanotechnology in medicine","volume":"130","author":"Surendiran","year":"2009","journal-title":"Indian J. Med. Res."},{"key":"10.1016\/j.ejpb.2015.03.018_b1190","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.drudis.2011.09.015","article-title":"Liposomal drug formulations in cancer therapy: 15 years along the road","volume":"17","author":"Slingerland","year":"2012","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejpb.2015.03.018_b1195","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.jconrel.2012.09.006","article-title":"Liposomal paclitaxel formulations","volume":"163","author":"Koudelka","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2015.03.018_b1200","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1089\/jam.2006.19.385","article-title":"Assessing a system to capture stray aerosol during inhalation of nebulized liposomal cisplatin","volume":"19","author":"Wittgen","year":"2006","journal-title":"J. Aerosol Med."},{"key":"10.1016\/j.ejpb.2015.03.018_b1205","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1166\/jbn.2008.334","article-title":"Inhaled liposomes current strategies and future challenges","volume":"4","author":"Gaspar","year":"2008","journal-title":"J. Biomed. Nanotechnol."},{"key":"10.1016\/j.ejpb.2015.03.018_b1210","first-page":"2748","article-title":"Phase II study of OSI-211 (liposomal lurtotecan) in patients with metastatic or loco-regional recurrent squamous cell carcinoma of the head and neck: an EORTC New Drug Development Group Study","volume":"40","author":"Duffaud","year":"2004","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejpb.2015.03.018_b1215","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ygyno.2003.12.037","article-title":"A phase II study of liposomal lurtotecan (OSI-211) in patients with topotecan resistant ovarian cancer","volume":"93","author":"Seiden","year":"2004","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ejpb.2015.03.018_b1220","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/S0145-2126(03)00092-4","article-title":"OSI-211, a novel liposomal topoisomerase I inhibitor, is active in SCID mouse models of human AML and ALL","volume":"27","author":"Tomkinson","year":"2003","journal-title":"Leuk. Res."},{"key":"10.1016\/j.ejpb.2015.03.018_b1225","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1023\/B:DRUG.0000026252.86842.e2","article-title":"A phase 1 study of OSI-211 given as an intravenous infusion days 1, 2, and 3 every three weeks in patients with solid cancers","volume":"22","author":"Gelmon","year":"2004","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.ejpb.2015.03.018_b1230","doi-asserted-by":"crossref","first-page":"5487","DOI":"10.1158\/1078-0432.CCR-05-0104","article-title":"Phase I study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor in patients with refractory solid tumors","volume":"11","author":"Beutel","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejpb.2015.03.018_b1235","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s00280-007-0509-5","article-title":"A phase I and pharmacokinetic study of OSI-7904L, a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancer","volume":"61","author":"Clamp","year":"2008","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejpb.2015.03.018_b1240","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/sj.bjc.6603267","article-title":"Multicentre phase II pharmacokinetic and pharmacodynamic study of OSI-7904L in previously untreated patients with advanced gastric or gastroesophageal junction adenocarcinoma","volume":"95","author":"Falk","year":"2006","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejpb.2015.03.018_b1245","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s00280-002-0464-0","article-title":"Phase II study of liposomal annamycin in the treatment of doxorubicin-resistant breast cancer","volume":"50","author":"Booser","year":"2002","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejpb.2015.03.018_b1250","series-title":"Safety of Nanoparticles","first-page":"209","article-title":"Nanoparticles for cancer diagnosis and therapy","author":"Wang","year":"2009"},{"key":"10.1016\/j.ejpb.2015.03.018_b1255","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1053\/beha.2003.0234","article-title":"New agents in the treatment of acute lymphocytic leukaemia","volume":"15","author":"Thomas","year":"2002","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"10.1016\/j.ejpb.2015.03.018_b1260","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s00280-012-2048-y","article-title":"A phase I study of liposomal-encapsulated docetaxel (LE-DT) in patients with advanced solid tumor malignancies","volume":"71","author":"Deeken","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejpb.2015.03.018_b1265","first-page":"11","article-title":"A liposomal formulation able to incorporate a high content of paclitaxel and exert promising anticancer effect","volume":"629234","author":"Kan","year":"2011","journal-title":"J. Drug Deliv."},{"key":"10.1016\/j.ejpb.2015.03.018_b1270","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ijpharm.2003.10.015","article-title":"Development and characterization of a novel liposome-based formulation of SN-38","volume":"270","author":"Zhang","year":"2004","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2015.03.018_b1275","first-page":"331","article-title":"Preclinical safety, pharmacokinetics and antitumor efficacy profile of liposome-entrapped SN-38 formulation","volume":"25","author":"Pal","year":"2005","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ejpb.2015.03.018_b1280","doi-asserted-by":"crossref","unstructured":"P.J. Gaillard, W. Gladdines, C.C. Apperldorn, J. Rip, W.J. Boogerd, J.H. Beijnen, D. Brandsma, O.v. Tellingen, Development of glutathione pegylated liposomal doxorubicin (2B3-101) for the treatment of brain cancer, in: AACR 103rd Annual Meeting 2012, American Association for Cancer Research, Chicago, IL, USA, 2012.","DOI":"10.1158\/1538-7445.AM2012-5687"},{"key":"10.1016\/j.ejpb.2015.03.018_b1285","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s00280-006-0235-4","article-title":"A phase 2 trial of the liposomal DACH platinum L-NDDP in patients with therapy-refractory advanced colorectal cancer","volume":"58","author":"Dragovich","year":"2006","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejpb.2015.03.018_b1290","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1200\/JCO.2005.00.802","article-title":"Phase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally and pathologic response rates in patients with malignant pleural mesothelioma","volume":"23","author":"Lu","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejpb.2015.03.018_b1295","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/164506","article-title":"Nano-oncology: clinical application for cancer therapy and future perspectives","author":"Riggio","year":"2011","journal-title":"J. Nanomater."},{"key":"10.1016\/j.ejpb.2015.03.018_b1300","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1158\/1078-0432.CCR-08-1405","article-title":"Phase I and pharmacokinetic study of pegylated liposomal CKD-602 in patients with advanced malignancies","volume":"15","author":"Zamboni","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejpb.2015.03.018_b1305","doi-asserted-by":"crossref","unstructured":"A.C. Mita, N.N. Senzer, S. Vemulapalli, J. Sarantopoulos, D. Mahalingam, M.M. Mita, J. Hart, N.S. Gallegos, G. Anderson, J. Charles, A. Kosuba, J.M. Rogers, J.J. Nemunaitis, ATI-1123, a novel human albumin-stabilized docetaxel liposomal formulation: final results of a phase I study in patients with advanced solid malignancies, in: AACR-NCI-EORTC International Conference. Molecular Targets and Cancer Therapeutics, San Francisco, CA, USA, 2011.","DOI":"10.1158\/1535-7163.TARG-11-A113"},{"key":"10.1016\/j.ejpb.2015.03.018_b1310","doi-asserted-by":"crossref","unstructured":"D. Mahalingam, A. Mita, A. Kousba, S. Vemulapalli, N. Gallegos, G. Anderson, J. Charles, J.M. Rogers, J. Sarantopoulos, M. Mita, N. Senzer, J. Nemunaitis, Phase 1 pharmacokinetic (PK) assessments of ATI-1123, a novel human serum albumin-stabilized nanoparticle docetaxel liposomal formulation, in patients with advanced solid malignancies, in: AACR-NCI-EORTC International Conference. Molecular Targets and Cancer Therapeutics, Molecular Cancer Therapeutics, San Francisco, CA, USA, 2011.","DOI":"10.1158\/1535-7163.TARG-11-B191"},{"key":"10.1016\/j.ejpb.2015.03.018_b1315","first-page":"189","article-title":"Antitumor activity of IHL-305, a novel pegylated liposome containing irinotecan, in human xenograft models","volume":"27","author":"Matsuzaki","year":"2012","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.ejpb.2015.03.018_b1320","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1158\/1078-0432.CCR-05-1260","article-title":"Phase I study of liposome-encapsulated c-raf antisense oligodeoxyribonucleotide infusion in combination with radiation therapy in patients with advanced malignancies","volume":"12","author":"Dritschilo","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejpb.2015.03.018_b1325","doi-asserted-by":"crossref","first-page":"7244","DOI":"10.1158\/1078-0432.CCR-04-0642","article-title":"Delivery of a liposomal c-raf-1 antisense oligonucleotide by weekly bolus dosing in patients with advanced solid tumors: a phase I study","volume":"10","author":"Rudin","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejpb.2015.03.018_b1330","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1006\/cyto.2000.0769","article-title":"Biopharmaceutics of liposomal interleukin 2, oncolipin","volume":"12","author":"Neville","year":"2000","journal-title":"Cytokine"},{"key":"10.1016\/j.ejpb.2015.03.018_b1335","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1517\/17425247.2010.538678","article-title":"Use of nanoscale delivery systems to maintain synergistic drug ratios in vivo","volume":"7","author":"Dicko","year":"2010","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ejpb.2015.03.018_b1340","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1517\/17425247.2013.758631","article-title":"Hyperthermia-induced drug targeting","volume":"10","author":"May","year":"2013","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ejpb.2015.03.018_b1345","doi-asserted-by":"crossref","unstructured":"J.E. Lancet, J.E. Cortes, D.E. Hogge, M. Tallman, T. Kovacsovics, L.E. Damon, E. Ritchie, R.S. Komrokji, A.C. Louie, E.J. Feldman, Phase 2B randomized study of CPX-351 vs. cytarabine (CYT) + daunorubicin (DNR) (7+3 regimen) in newly diagnosed AML patients aged 60\u201375, in: 53rd ASH Annual Meeting and Exposition, 2011.","DOI":"10.1200\/jco.2011.29.15_suppl.6519"},{"key":"10.1016\/j.ejpb.2015.03.018_b1350","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1200\/JCO.2010.30.5961","article-title":"First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia","volume":"29","author":"Feldman","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejpb.2015.03.018_b1355","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.leukres.2012.07.006","article-title":"Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin, in patients with advanced leukemia","volume":"36","author":"Feldman","year":"2012","journal-title":"Leuk. Res."},{"key":"10.1016\/j.ejpb.2015.03.018_b1360","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1158\/1078-0432.CCR-08-0515","article-title":"Safety, pharmacokinetics, and efficacy of CPX-1 liposome injection in patients with advanced solid tumors","volume":"15","author":"Batist","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejpb.2015.03.018_b1365","doi-asserted-by":"crossref","unstructured":"B. O\u2019Connor, S. Lewis, N. Borys, Phase I\/II study evaluating the maximum tolerated dose, pharmacokinetics, safety, and efficacy of hyperthermia and lyso-thermosensitive liposomal doxorubicin in patients with breast cancer recurrence at the chest wall, in: 2010 Breast Cancer Symposium, ASCO University, 2010.","DOI":"10.1016\/j.ijrobp.2010.07.608"},{"key":"10.1016\/j.ejpb.2015.03.018_b1370","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.jvir.2011.10.018","article-title":"Phase I study of heat-deployed liposomal doxorubicin during radiofrequency ablation for hepatic malignancies","volume":"23","author":"Wood","year":"2012","journal-title":"J. Vasc. Interv. Radiol."},{"key":"10.1016\/j.ejpb.2015.03.018_b1375","first-page":"1172","article-title":"Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery","volume":"8","author":"Park","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejpb.2015.03.018_b1380","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ijpharm.2009.03.018","article-title":"Tumor-targeted PE38KDEL delivery via PEGylated anti-HER2 immunoliposomes","volume":"374","author":"Gao","year":"2009","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2015.03.018_b1385","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1093\/annonc\/mdh092","article-title":"Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer","volume":"15","author":"Matsumura","year":"2004","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejpb.2015.03.018_b1390","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ijpharm.2007.06.010","article-title":"Effective anti-tumor activity of oxaliplatin encapsulated in transferrin\u2013PEG-liposome","volume":"346","author":"Suzuki","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2015.03.018_b1395","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.addr.2013.08.012","article-title":"Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status","volume":"65","author":"van der Meel","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2015.03.018_b1400","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4143\/crt.2009.41.1.1","article-title":"Advances of cancer therapy by nanotechnology","volume":"41","author":"Wang","year":"2009","journal-title":"Cancer Res. Treat."},{"key":"10.1016\/j.ejpb.2015.03.018_b1405","doi-asserted-by":"crossref","first-page":"3","DOI":"10.7150\/thno.3463","article-title":"Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy","volume":"2","author":"Yu","year":"2012","journal-title":"Theranostics"},{"key":"10.1016\/j.ejpb.2015.03.018_b1410","series-title":"Methods in Enzymology","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0076-6879(09)64017-9","article-title":"Engineering cationic liposome: siRNA complexes for in vitro and in vivo delivery","author":"Podesta","year":"2009"},{"key":"10.1016\/j.ejpb.2015.03.018_b1415","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1038\/mtna.2011.9","article-title":"The business of RNAi therapeutics in 2012","volume":"1","author":"Haussecker","year":"2012","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ejpb.2015.03.018_b1420","series-title":"Liposomes","first-page":"445","article-title":"Liposomal siRNA delivery","author":"Hughes","year":"2010"},{"key":"10.1016\/j.ejpb.2015.03.018_b1425","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3390\/ph6010085","article-title":"Nanoparticle-based delivery of RNAi therapeutics: progress and challenges","volume":"6","author":"Zhou","year":"2013","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejpb.2015.03.018_b1430","doi-asserted-by":"crossref","first-page":"9788","DOI":"10.1158\/0008-5472.CAN-08-2428","article-title":"Atu027, a liposomal small interfering RNA formulation targeting protein kinase N3, inhibits cancer progression","volume":"68","author":"Aleku","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejpb.2015.03.018_b1435","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1002\/biot.201100054","article-title":"Current progress of siRNA\/shRNA therapeutics in clinical trials","volume":"6","author":"Burnett","year":"2011","journal-title":"Biotechnol. J."},{"key":"10.1016\/j.ejpb.2015.03.018_b1440","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/mt.2011.263","article-title":"Progress toward in vivo use of siRNAs-II","volume":"20","author":"Rettig","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ejpb.2015.03.018_b1445","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/mt.2013.32","article-title":"Phase I study of a systemically delivered p53 nanoparticle in advanced solid tumors","volume":"21","author":"Senzer","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ejpb.2015.03.018_b1450","doi-asserted-by":"crossref","first-page":"E1330","DOI":"10.1073\/pnas.1110013108","article-title":"Diameter and rigidity of multiwalled carbon nanotubes are critical factors in mesothelial injury and carcinogenesis","volume":"108","author":"Nagai","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejpb.2015.03.018_b1455","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1109\/TNB.2005.850478","article-title":"Carbon nanotubes for biomedical applications","volume":"4","author":"Sinha","year":"2005","journal-title":"IEEE Trans. NanoBiosci."},{"key":"10.1016\/j.ejpb.2015.03.018_b1460","first-page":"5361","article-title":"Functionalized carbon nanotubes: biomedical applications","volume":"7","author":"Vardharajula","year":"2012","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.ejpb.2015.03.018_b1465","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1002\/smll.201101004","article-title":"Cellular uptake and cytotoxic impact of chemically functionalized and polymer-coated carbon nanotubes","volume":"7","author":"Ali-Boucetta","year":"2011","journal-title":"Small"},{"key":"10.1016\/j.ejpb.2015.03.018_b1470","doi-asserted-by":"crossref","first-page":"10182","DOI":"10.1039\/c1cc13011k","article-title":"Making carbon nanotubes biocompatible and biodegradable","volume":"47","author":"Bianco","year":"2011","journal-title":"Chem. Commun."},{"key":"10.1016\/j.ejpb.2015.03.018_b1475","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1021\/nn800395t","article-title":"Enhancement of in vivo anticancer effects of cisplatin by incorporation inside single-wall carbon nanohorns","volume":"2","author":"Ajima","year":"2008","journal-title":"ACS Nano"},{"key":"10.1016\/j.ejpb.2015.03.018_b1480","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2217\/17435889.3.2.175","article-title":"Carbon nanotubes filled with a chemotherapeutic agent: a nanocarrier mediates inhibition of tumor cell growth","volume":"3","author":"Hampel","year":"2008","journal-title":"Nanomedicine"},{"key":"10.1016\/j.ejpb.2015.03.018_b1485","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1021\/nn9005686","article-title":"Covalently combining carbon nanotubes with anticancer agent: preparation and antitumor activity","volume":"3","author":"Wu","year":"2009","journal-title":"ACS Nano"},{"key":"10.1016\/j.ejpb.2015.03.018_b1490","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/anie.200503389","article-title":"Carbon nanotubes as intracellular transporters for proteins and DNA: an investigation of the uptake mechanism and pathway","volume":"45","author":"Kam","year":"2006","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejpb.2015.03.018_b1495","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nnano.2006.209","article-title":"Cellular uptake of functionalized carbon nanotubes is independent of functional group and cell type","volume":"2","author":"Kostarelos","year":"2007","journal-title":"Nat. Nano"},{"key":"10.1016\/j.ejpb.2015.03.018_b1500","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.1039\/c2cc17995d","article-title":"Targeting carbon nanotubes against cancer","volume":"48","author":"Fabbro","year":"2012","journal-title":"Chem. Commun."},{"key":"10.1016\/j.ejpb.2015.03.018_b1505","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nnano.2006.170","article-title":"In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice","volume":"2","author":"Liu","year":"2007","journal-title":"Nat. Nano"},{"key":"10.1016\/j.ejpb.2015.03.018_b1510","doi-asserted-by":"crossref","first-page":"11467","DOI":"10.1021\/ja803036e","article-title":"Targeted single-wall carbon nanotube-mediated Pt(IV) prodrug delivery using folate as a homing device","volume":"130","author":"Dhar","year":"2008","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejpb.2015.03.018_b1515","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.2967\/jnumed.106.039131","article-title":"Tumor targeting with antibody-functionalized, radiolabeled carbon nanotubes","volume":"48","author":"McDevitt","year":"2007","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejpb.2015.03.018_b1520","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1016\/j.carbon.2009.03.057","article-title":"Triple functionalisation of single-walled carbon nanotubes with doxorubicin, a monoclonal antibody, and a fluorescent marker for targeted cancer therapy","volume":"47","author":"Heister","year":"2009","journal-title":"Carbon"},{"key":"10.1016\/j.ejpb.2015.03.018_b1525","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1016\/j.biomaterials.2009.07.025","article-title":"Targeted delivery and controlled release of doxorubicin to cancer cells using modified single wall carbon nanotubes","volume":"30","author":"Zhang","year":"2009","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejpb.2015.03.018_b1530","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1021\/nn9011225","article-title":"P-glycoprotein antibody functionalized carbon nanotube overcomes the multidrug resistance of human leukemia cells","volume":"4","author":"Li","year":"2010","journal-title":"ACS Nano"},{"key":"10.1016\/j.ejpb.2015.03.018_b1535","doi-asserted-by":"crossref","first-page":"6652","DOI":"10.1158\/0008-5472.CAN-08-1468","article-title":"Drug delivery with carbon nanotubes for in vivo cancer treatment","volume":"68","author":"Liu","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejpb.2015.03.018_b1540","doi-asserted-by":"crossref","first-page":"7668","DOI":"10.1002\/anie.200902612","article-title":"Supramolecular stacking of doxorubicin on carbon nanotubes for in vivo cancer therapy","volume":"48","author":"Liu","year":"2009","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejpb.2015.03.018_b1545","doi-asserted-by":"crossref","first-page":"8438","DOI":"10.1021\/ja073231f","article-title":"Soluble single-walled carbon nanotubes as longboat delivery systems for platinum(IV) anticancer drug design","volume":"129","author":"Feazell","year":"2007","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejpb.2015.03.018_b1550","doi-asserted-by":"crossref","first-page":"335101","DOI":"10.1088\/0957-4484\/21\/33\/335101","article-title":"Delivery of carboplatin by carbon-based nanocontainers mediates increased cancer cell death","volume":"21","author":"Arlt","year":"2010","journal-title":"Nanotechnology"},{"key":"10.1016\/j.ejpb.2015.03.018_b1555","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.addr.2011.06.013","article-title":"Polymeric nanohybrids and functionalized carbon nanotubes as drug delivery carriers for cancer therapy","volume":"63","author":"Prakash","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2015.03.018_b1560","doi-asserted-by":"crossref","first-page":"025102","DOI":"10.1088\/0957-4484\/21\/2\/025102","article-title":"Single-walled carbon nanotube-conjugated chemotherapy exhibits increased therapeutic index in melanoma","volume":"21","author":"Chaudhuri","year":"2010","journal-title":"Nanotechnology"},{"key":"10.1016\/j.ejpb.2015.03.018_b1565","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1039\/B923560D","article-title":"Enhanced anticancer activity of multi-walled carbon nanotube-methotrexate conjugates using cleavable linkers","volume":"46","author":"Samori","year":"2010","journal-title":"Chem. Commun."},{"key":"10.1016\/j.ejpb.2015.03.018_b1570","first-page":"705","article-title":"Increased paclitaxel cytotoxicity against cancer cell lines using a novel functionalized carbon nanotube","volume":"6","author":"Sobhani","year":"2011","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.ejpb.2015.03.018_b1575","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.cplett.2009.07.071","article-title":"Single-wall carbon nanotubes based anticancer drug delivery system","volume":"478","author":"Tripisciano","year":"2009","journal-title":"Chem. Phys. Lett."},{"key":"10.1016\/j.ejpb.2015.03.018_b1580","doi-asserted-by":"crossref","first-page":"5231","DOI":"10.1039\/c3cs35431h","article-title":"Carbon nanotubes in cancer therapy: a more precise look at the role of carbon nanotube-polymer interactions","volume":"42","author":"Adeli","year":"2013","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ejpb.2015.03.018_b1585","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/S1369-7021(11)70161-4","article-title":"Carbon materials for drug delivery & cancer therapy","volume":"14","author":"Liu","year":"2011","journal-title":"Mater. Today"},{"key":"10.1016\/j.ejpb.2015.03.018_b1590","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/j.addr.2013.08.005","article-title":"Carbon nanotubes for delivery of small molecule drugs","volume":"65","author":"Wong","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2015.03.018_b1595","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1021\/nl801362a","article-title":"Noninvasive Raman spectroscopy in living mice for evaluation of tumor targeting with carbon nanotubes","volume":"8","author":"Zavaleta","year":"2008","journal-title":"Nano Lett."},{"key":"10.1016\/j.ejpb.2015.03.018_b1600","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.2217\/nnm.10.90","article-title":"Distribution and clearance of PEG-single-walled carbon nanotube cancer drug delivery vehicles in mice","volume":"5","author":"Bhirde","year":"2010","journal-title":"Nanomedicine"},{"key":"10.1016\/j.ejpb.2015.03.018_b1605","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1021\/nn800551s","article-title":"Targeted killing of cancer cells in vivo and in vitro with EGF-directed carbon nanotube-based drug delivery","volume":"3","author":"Bhirde","year":"2009","journal-title":"ACS Nano"},{"key":"10.1016\/j.ejpb.2015.03.018_b1610","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.cbpa.2005.10.005","article-title":"Applications of carbon nanotubes in drug delivery","volume":"9","author":"Bianco","year":"2005","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.ejpb.2015.03.018_b1615","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s12274-009-9009-8","article-title":"Carbon nanotubes in biology and medicine: in vitro and in vivo detection, imaging and drug delivery","volume":"2","author":"Liu","year":"2009","journal-title":"Nano Res."},{"key":"10.1016\/j.ejpb.2015.03.018_b1620","doi-asserted-by":"crossref","first-page":"6358","DOI":"10.1002\/anie.200501613","article-title":"Targeted delivery of amphotericin B to cells by using functionalized carbon nanotubes","volume":"44","author":"Wu","year":"2005","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejpb.2015.03.018_b1625","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.2147\/IJN.S24167","article-title":"Synergistic enhancement of cancer therapy using a combination of docetaxel and photothermal ablation induced by single-walled carbon nanotubes","volume":"6","author":"Wang","year":"2011","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.ejpb.2015.03.018_b1630","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jcis.2011.09.013","article-title":"Targeted therapy of SMMC-7721 liver cancer in vitro and in vivo with carbon nanotubes based drug delivery system","volume":"365","author":"Ji","year":"2012","journal-title":"J. Colloid Interface Sci."},{"key":"10.1016\/j.ejpb.2015.03.018_b1635","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1021\/bc300248t","article-title":"Hyaluronate tethered, \u201csmart\u201d multiwalled carbon nanotubes for tumor-targeted delivery of doxorubicin","volume":"23","author":"Datir","year":"2012","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ejpb.2015.03.018_b1640","doi-asserted-by":"crossref","first-page":"3324","DOI":"10.1016\/j.biomaterials.2012.01.025","article-title":"The targeted delivery of anticancer drugs to brain glioma by PEGylated oxidized multi-walled carbon nanotubes modified with angiopep-2","volume":"33","author":"Ren","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejpb.2015.03.018_b1645","doi-asserted-by":"crossref","first-page":"581","DOI":"10.3109\/1061186X.2013.778264","article-title":"Gemcitabine-loaded smart carbon nanotubes for effective targeting to cancer cells","volume":"21","author":"Singh","year":"2013","journal-title":"J. Drug Target."},{"key":"10.1016\/j.ejpb.2015.03.018_b1650","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S0169-409X(02)00228-4","article-title":"Biodegradable nanoparticles for drug and gene delivery to cells and tissue","volume":"55","author":"Panyam","year":"2003","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2015.03.018_b1655","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0168-3659(03)00328-6","article-title":"Polymer degradation and in vitro release of a model protein from poly(d,l-lactide-co-glycolide) nano- and microparticles","volume":"92","author":"Panyam","year":"2003","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2015.03.018_b1660","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11095-006-9132-0","article-title":"Micellar nanocarriers: pharmaceutical perspectives","volume":"24","author":"Torchilin","year":"2007","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2015.03.018_b1665","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v20.i5.20","article-title":"Polymeric micelles for delivery of poorly water-soluble compounds","volume":"20","author":"Kwon","year":"2003","journal-title":"Crit. Rev. Ther. Drug Carrier Syst."},{"key":"10.1016\/j.ejpb.2015.03.018_b1670","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1080\/15583720701455079","article-title":"Anticancer polymeric nanomedicines","volume":"47","author":"Tong","year":"2007","journal-title":"Polym. Rev."},{"key":"10.1016\/j.ejpb.2015.03.018_b1675","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/0169-409X(95)00031-2","article-title":"Block copolymer micelles as long-circulating drug vehicles","volume":"16","author":"Kwon","year":"1995","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2015.03.018_b1680","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/nnano.2011.166","article-title":"Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size","volume":"6","author":"Cabral","year":"2011","journal-title":"Nat. Nano"},{"issue":"1","key":"10.1016\/j.ejpb.2015.03.018_b9005","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ijpharm.2012.08.042","article-title":"Polymeric micelles and alternative nanosized delivery vehicles for poorly soluble drugs","volume":"453","author":"Lu","year":"2013","journal-title":"Int. J. Pharmaceut."},{"key":"10.1016\/j.ejpb.2015.03.018_b1690","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.cossms.2012.10.003","article-title":"Polymeric micelles for cancer therapy: 3 C\u2019s to enhance efficacy","volume":"16","author":"Talelli","year":"2012","journal-title":"Curr. Opin. Solid State Mater. Sci."},{"key":"10.1016\/j.ejpb.2015.03.018_b1695","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1007\/s11095-010-0233-4","article-title":"Polymeric micelles in anticancer therapy: targeting, imaging and triggered release","volume":"27","author":"Oerlemans","year":"2010","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2015.03.018_b1700","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.progpolymsci.2007.05.009","article-title":"Physical stimuli-responsive polymeric micelles for anti-cancer drug delivery","volume":"32","author":"Rapoport","year":"2007","journal-title":"Prog. Polym. Sci."},{"key":"10.1016\/j.ejpb.2015.03.018_b1705","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1021\/bm900074d","article-title":"PH-responsive biodegradable micelles based on acid-labile polycarbonate hydrophobe: synthesis and triggered drug release","volume":"10","author":"Chen","year":"2009","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.ejpb.2015.03.018_b1710","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1021\/ma902227g","article-title":"Aqueous solution properties of the acid-labile thermoresponsive poly(meth)acrylamides with pendent cyclic orthoester groups","volume":"43","author":"Du","year":"2010","journal-title":"Macromolecules"},{"key":"10.1016\/j.ejpb.2015.03.018_b1715","doi-asserted-by":"crossref","first-page":"13201","DOI":"10.1021\/la9018794","article-title":"High-frequency ultrasound-responsive block copolymer micelle","volume":"25","author":"Wang","year":"2009","journal-title":"Langmuir"},{"issue":"4","key":"10.1016\/j.ejpb.2015.03.018_b1720","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/j.1751-1097.2008.00530.x","article-title":"Light-sensitive intelligent drug delivery systems","volume":"85","author":"Alvarez-Lorenzo","year":"2009","journal-title":"Photochem. Photobiol."},{"key":"10.1016\/j.ejpb.2015.03.018_b1725","doi-asserted-by":"crossref","first-page":"7797","DOI":"10.1016\/j.biomaterials.2010.07.005","article-title":"Core-crosslinked polymeric micelles with controlled release of covalently entrapped doxorubicin","volume":"31","author":"Talelli","year":"2010","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejpb.2015.03.018_b1730","series-title":"Polymeric Drug Delivery Systems","first-page":"491","article-title":"Polymer assemblies: intelligent block copolymers micelles for the programmed delivery of drugs and genes","author":"Bae","year":"2005"},{"key":"10.1016\/j.ejpb.2015.03.018_b1735","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s10637-010-9399-1","article-title":"A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction","volume":"29","author":"Valle","year":"2011","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.ejpb.2015.03.018_b1740","doi-asserted-by":"crossref","first-page":"6039","DOI":"10.1073\/pnas.0931428100","article-title":"Immunomicelles: targeted pharmaceutical carriers for poorly soluble drugs","volume":"100","author":"Torchilin","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejpb.2015.03.018_b1745","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ijpharm.2008.12.035","article-title":"9-NC-loaded folate-conjugated polymer micelles as tumor targeted drug delivery system: preparation and evaluation in vitro","volume":"372","author":"Han","year":"2009","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2015.03.018_b1750","doi-asserted-by":"crossref","first-page":"6323","DOI":"10.1002\/anie.200460800","article-title":"CRGD-functionalized polymer micelles for targeted doxorubicin delivery","volume":"43","author":"Nasongkla","year":"2004","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejpb.2015.03.018_b1755","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1039\/b500266d","article-title":"Multifunctional polymeric micelles with folate-mediated cancer cell targeting and pH-triggered drug releasing properties for active intracellular drug delivery","volume":"1","author":"Bae","year":"2005","journal-title":"Mol. BioSyst."},{"key":"10.1016\/j.ejpb.2015.03.018_b1760","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1021\/bc9005283","article-title":"Tumor-targeting peptide conjugated pH-responsive micelles as a potential drug carrier for cancer therapy","volume":"21","author":"Wu","year":"2010","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ejpb.2015.03.018_b1765","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jconrel.2011.12.012","article-title":"Polymeric micelles drug delivery system in oncology","volume":"159","author":"Gong","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2015.03.018_b1770","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ijpharm.2012.08.042","article-title":"Polymeric micelles and alternative nanonized delivery vehicles for poorly soluble drugs","volume":"453","author":"Lu","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2015.03.018_b1775","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s10549-007-9591-y","article-title":"Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer","volume":"108","author":"Lee","year":"2008","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.ejpb.2015.03.018_b1780","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1093\/annonc\/mdm374","article-title":"Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer","volume":"18","author":"Kim","year":"2007","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejpb.2015.03.018_b1785","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jconrel.2011.06.012","article-title":"Development of docetaxel-loaded intravenous formulation, Nanoxel-PM\u2122 using polymer-based delivery system","volume":"155","author":"Lee","year":"2011","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2015.03.018_b1790","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1038\/sj.bjc.6602204","article-title":"Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin","volume":"91","author":"Matsumura","year":"2004","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejpb.2015.03.018_b1795","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1007\/s10637-011-9709-2","article-title":"Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer","volume":"30","author":"Kato","year":"2012","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.ejpb.2015.03.018_b1800","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/sj.bjc.6603855","article-title":"A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation","volume":"97","author":"Hamaguchi","year":"2007","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejpb.2015.03.018_b1805","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/bjc.2011.6","article-title":"A phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours","volume":"104","author":"Plummer","year":"2011","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejpb.2015.03.018_b1810","doi-asserted-by":"crossref","first-page":"5058","DOI":"10.1158\/1078-0432.CCR-10-0387","article-title":"Phase I study of NK012, a novel SN-38-incorporating micellar nanoparticle, in adult patients with solid tumors","volume":"16","author":"Hamaguchi","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejpb.2015.03.018_b1815","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ejps.2009.07.008","article-title":"Dendrimers: emerging polymers for drug-delivery systems","volume":"38","author":"Nanjwade","year":"2009","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2015.03.018_b1820","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.2741\/2774","article-title":"Pharmaceutical applications of dendrimers: promising nanocarriers for drug delivery","volume":"13","author":"Cheng","year":"2008","journal-title":"Front. Biosci."},{"key":"10.1016\/j.ejpb.2015.03.018_b1825","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.addr.2008.02.012","article-title":"Therapeutic and diagnostic applications of dendrimers for cancer treatment","volume":"60","author":"Wolinsky","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2015.03.018_b1830","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1177\/153303460500400604","article-title":"In vivo biodistribution of dendrimers and dendrimer nanocomposites \u2013 implications for cancer imaging and therapy","volume":"4","author":"Khan","year":"2005","journal-title":"Technol. Cancer Res. Treat."},{"key":"10.1016\/j.ejpb.2015.03.018_b1835","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1038\/nbt1171","article-title":"Designing dendrimers for biological applications","volume":"23","author":"Lee","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ejpb.2015.03.018_b1840","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.ejpb.2008.09.023","article-title":"Dendrimers as versatile platform in drug delivery applications","volume":"71","author":"Svenson","year":"2009","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2015.03.018_b1845","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1021\/bc0000583","article-title":"Synthesis of polyamidoamine dendrimers having poly(ethylene glycol) grafts and their ability to encapsulate anticancer drugs","volume":"11","author":"Kojima","year":"2000","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ejpb.2015.03.018_b1850","doi-asserted-by":"crossref","first-page":"15485","DOI":"10.1021\/ja0347383","article-title":"Dendritic molecular capsules for hydrophobic compounds","volume":"125","author":"Morgan","year":"2003","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejpb.2015.03.018_b1855","doi-asserted-by":"crossref","first-page":"11913","DOI":"10.1158\/0008-5472.CAN-06-2066","article-title":"Dendrimer-encapsulated camptothecins: increased solubility, cellular uptake, and cellular retention affords enhanced anticancer activity in vitro","volume":"66","author":"Morgan","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejpb.2015.03.018_b1860","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1097\/00001813-199909000-00010","article-title":"Dendrimer-platinate: a novel approach to cancer chemotherapy","volume":"10","author":"Malik","year":"1999","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.ejpb.2015.03.018_b1865","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1016\/j.biomaterials.2007.03.012","article-title":"Influence of molecular architecture of polyether-co-polyester dendrimers on the encapsulation and release of methotrexate","volume":"28","author":"Dhanikula","year":"2007","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejpb.2015.03.018_b1870","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1021\/bc0501855","article-title":"Activity of dendrimer\u2013methotrexate conjugates on methotrexate-sensitive and -resistant cell lines","volume":"17","author":"Gurdag","year":"2006","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ejpb.2015.03.018_b1875","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1021\/bc060240p","article-title":"Dendrimer versus linear conjugate: influence of polymeric architecture on the delivery and anticancer effect of paclitaxel","volume":"17","author":"Khandare","year":"2006","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ejpb.2015.03.018_b1880","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1021\/ol7024907","article-title":"Synthesis of water-soluble dendrimers based on melamine bearing 16 paclitaxel groups","volume":"10","author":"Lim","year":"2007","journal-title":"Org. Lett."},{"key":"10.1016\/j.ejpb.2015.03.018_b1885","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1021\/bc010103m","article-title":"Polyester dendritic systems for drug delivery applications: in vitro and in vivo evaluation","volume":"13","author":"Padilla De Jes\u00fas","year":"2002","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ejpb.2015.03.018_b1890","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1007\/s10856-013-4969-3","article-title":"Encapsulation of curcumin within poly(amidoamine) dendrimers for delivery to cancer cells","volume":"24","author":"Wang","year":"2013","journal-title":"J. Mater. Sci. \u2013 Mater. Med."},{"key":"10.1016\/j.ejpb.2015.03.018_b1895","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1166\/jbn.2013.1479","article-title":"Pegylated dendrimer and its effect in fluorouracil loading and release for enhancing antitumor activity","volume":"9","author":"Ly","year":"2013","journal-title":"J. Biomed. Nanotechnol."},{"key":"10.1016\/j.ejpb.2015.03.018_b1900","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1021\/bc050348p","article-title":"HER2 specific tumor targeting with dendrimer conjugated anti-HER2 mAb","volume":"17","author":"Shukla","year":"2006","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ejpb.2015.03.018_b1905","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1021\/bc0499127","article-title":"Synthesis and in vitro testing of J591 antibody\u2013dendrimer conjugates for targeted prostate cancer therapy","volume":"15","author":"Patri","year":"2004","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ejpb.2015.03.018_b1910","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1021\/bm049704h","article-title":"In vitro targeting of synthesized antibody-conjugated dendrimer nanoparticles","volume":"5","author":"Thomas","year":"2004","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.ejpb.2015.03.018_b1915","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1158\/1535-7163.MCT-05-0325","article-title":"Targeted delivery of methotrexate to epidermal growth factor receptor-positive brain tumors by means of cetuximab (IMC-C225) dendrimer bioconjugates","volume":"5","author":"Wu","year":"2006","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ejpb.2015.03.018_b1920","doi-asserted-by":"crossref","first-page":"5739","DOI":"10.1039\/b507350b","article-title":"Tumor angiogenic vasculature targeting with PAMAM dendrimer-RGD conjugates","volume":"14","author":"Shukla","year":"2005","journal-title":"Chem. Commun."},{"key":"10.1016\/j.ejpb.2015.03.018_b1925","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1039\/b615940k","article-title":"Synthesis of DOTA-conjugated multivalent cyclic-RGD peptide dendrimers via 1,3-dipolar cycloaddition and their biological evaluation: implications for tumor targeting and tumor imaging purposes","volume":"5","author":"Dijkgraaf","year":"2007","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.ejpb.2015.03.018_b1930","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ejpb.2011.03.025","article-title":"RGD-modified PEG-PAMAM-DOX conjugates: in vitro and in vivo studies for glioma","volume":"79","author":"Zhang","year":"2011","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2015.03.018_b1935","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1021\/bc800125u","article-title":"Folate and folate\u2013PEG\u2013PAMAM dendrimers: synthesis, characterization, and targeted anticancer drug delivery potential in tumor bearing mice","volume":"19","author":"Singh","year":"2008","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ejpb.2015.03.018_b1940","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1021\/bc990082k","article-title":"Design of dendritic macromolecules containing folate or methotrexate residues","volume":"10","author":"Kono","year":"1999","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ejpb.2015.03.018_b1945","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1023\/A:1020398624602","article-title":"Design and function of a dendrimer-based therapeutic nanodevice targeted to tumor cells through the folate receptor","volume":"19","author":"Quintana","year":"2002","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2015.03.018_b1950","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jconrel.2013.08.115","article-title":"Folic acid-modified dendrimer-DOX conjugates for targeting cancer chemotherapy","volume":"172","author":"Zhang","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2015.03.018_b1955","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0168-3659(99)00246-1","article-title":"Dendrimers: relationship between structure and biocompatibility in vitro, and preliminary studies on the biodistribution of 125I-labelled polyamidoamine dendrimers in vivo","volume":"65","author":"Malik","year":"2000","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2015.03.018_b1960","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1016\/j.addr.2005.09.019","article-title":"Dendrimer biocompatibility and toxicity","volume":"57","author":"Duncan","year":"2005","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2015.03.018_b1965","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1021\/bc900553n","article-title":"Design, synthesis, and biological evaluation of a robust, biodegradable dendrimer","volume":"21","author":"van der Poll","year":"2010","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ejpb.2015.03.018_b1970","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1021\/mp8000292","article-title":"The role of the size and number of polyethylene glycol chains in the biodistribution and tumor localization of triazine dendrimers","volume":"5","author":"Lim","year":"2008","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2015.03.018_b1975","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/j.biochi.2010.02.017","article-title":"Functional dendritic polymer architectures as stimuli-responsive nanocarriers","volume":"92","author":"Calder\u00f3n","year":"2010","journal-title":"Biochimie"},{"key":"10.1016\/j.ejpb.2015.03.018_b1980","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.jconrel.2011.01.017","article-title":"Development of efficient acid cleavable multifunctional prodrugs derived from dendritic polyglycerol with a poly(ethylene glycol) shell","volume":"151","author":"Calder\u00f3n","year":"2011","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2015.03.018_b1985","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1002\/jps.21155","article-title":"Enhanced oral bioavailability of doxorubicin in a dendrimer drug delivery system","volume":"97","author":"Ke","year":"2008","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2015.03.018_b1990","doi-asserted-by":"crossref","first-page":"4304","DOI":"10.1016\/j.actbio.2012.07.031","article-title":"Reducing cytotoxicity while improving anti-cancer drug loading capacity of polypropylenimine dendrimers by surface acetylation","volume":"8","author":"Wang","year":"2012","journal-title":"Acta Biomater."},{"key":"10.1016\/j.ejpb.2015.03.018_b1995","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.ejmech.2013.09.019","article-title":"Thermoresponsive dendrimers based on oligoethylene glycols: design, synthesis and cytotoxic activity against MCF-7 breast cancer cells","volume":"69","author":"Abdel-Rahman","year":"2013","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejpb.2015.03.018_b2000","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1007\/s00018-009-0053-z","article-title":"Nanocarriers\u2019 entry into the cell: relevance to drug delivery","volume":"66","author":"Hillaireau","year":"2009","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.ejpb.2015.03.018_b2005","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jconrel.2006.05.017","article-title":"Heparin\u2013deoxycholic acid chemical conjugate as an anticancer drug carrier and its antitumor activity","volume":"114","author":"Park","year":"2006","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2015.03.018_b2010","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.addr.2003.10.040","article-title":"Polymeric anticancer drugs with pH-controlled activation","volume":"56","author":"Ulbrich","year":"2004","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2015.03.018_b2015","doi-asserted-by":"crossref","first-page":"323","DOI":"10.4155\/tde.10.13","article-title":"Nanoparticle-assisted combination therapies for effective cancer treatment","volume":"1","author":"Hu","year":"2010","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.ejpb.2015.03.018_b2020","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.addr.2008.09.001","article-title":"Polysaccharides-based nanoparticles as drug delivery systems","volume":"60","author":"Liu","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2015.03.018_b2025","doi-asserted-by":"crossref","first-page":"657","DOI":"10.4155\/tde.12.40","article-title":"Polymer-based oral peptide nanomedicines","volume":"3","author":"Herrero","year":"2012","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.ejpb.2015.03.018_b2030","first-page":"99","article-title":"Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancer","volume":"4","author":"Miele","year":"2009","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.ejpb.2015.03.018_b2035","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jconrel.2011.09.069","article-title":"Impact of albumin on drug delivery \u2013 new applications on the horizon","volume":"157","author":"Elsadek","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2015.03.018_b2040","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1248\/bpb.b12-01102","article-title":"Clinical application of drug delivery systems in cancer chemotherapy: review of the efficacy and side effects of approved drugs","volume":"36","author":"Iwamoto","year":"2013","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.ejpb.2015.03.018_b2045","unstructured":"FDA Approval for Paclitaxel Albumin-stabilized Nanoparticle Formulation, National Cancer Institute (National Institutes of Health), 2013."},{"key":"10.1016\/j.ejpb.2015.03.018_b2050","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.lungcan.2013.02.020","article-title":"Efficacy and safety of weekly nab-paclitaxel plus carboplatin in patients with advanced non-small cell lung cancer","volume":"81","author":"Satouchi","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ejpb.2015.03.018_b2055","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejpb.2015.03.018_b2060","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1002\/cncr.25659","article-title":"A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group Study, N057E(1)","volume":"117","author":"Kottschade","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.ejpb.2015.03.018_b2065","doi-asserted-by":"crossref","unstructured":"P. Merle, S.S. Ahmed, F. Habersetzer, A. Abergel, J. Taieb, L. Bonyhay, D. Costantini, J. Dufour-Lamartinie, C. Trepo, Phase 1 study of intra-arterial hepatic (IAH) delivery of doxorubicin-transdrug (DT) for patients with advanced hepatocellular carcinoma (HCC), in: 2006 ASCO Annual Meeting Proceedings, American Society of Clinical Oncology, 2006 (J. Clin. Oncol.).","DOI":"10.1016\/S1386-6532(06)80558-5"},{"key":"10.1016\/j.ejpb.2015.03.018_b2070","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/BF00877245","article-title":"Phase I clinical trial and pharmacokinetic evaluation of doxorubicin carried by polyisohexylcyanoacrylate nanoparticles","volume":"10","author":"Kattan","year":"1992","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.ejpb.2015.03.018_b2075","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.nano.2009.01.009","article-title":"A randomized multicenter phase II clinical trial of mitoxantrone-loaded nanoparticles in the treatment of 108 patients with unresected hepatocellular carcinoma","volume":"5","author":"Zhou","year":"2009","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"10.1016\/j.ejpb.2015.03.018_b2080","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jconrel.2011.03.007","article-title":"Preclinical to clinical development of the novel camptothecin nanopharmaceutical CRLX101","volume":"153","author":"Svenson","year":"2011","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2015.03.018_b2085","first-page":"314","article-title":"Nanoparticle Trojan horses gallop from the lab into the clinic","volume":"330","author":"R.F. Service, Nanotechnology","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejpb.2015.03.018_b2090","doi-asserted-by":"crossref","first-page":"3003651","DOI":"10.1126\/scitranslmed.3003651","article-title":"Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile","volume":"4","author":"Hrkach","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejpb.2015.03.018_b2095","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.copbio.2013.02.020","article-title":"Recent progress in nanomedicine: therapeutic, diagnostic and theranostic applications","volume":"24","author":"Rizzo","year":"2013","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.ejpb.2015.03.018_b2100","doi-asserted-by":"crossref","first-page":"262","DOI":"10.2174\/157489209789206869","article-title":"Nanoparticle albumin-bound (NAB) technology is a promising method for anti-cancer drug delivery","volume":"4","author":"Fu","year":"2009","journal-title":"Recent Pat. Anticancer Drug Discov."},{"key":"10.1016\/j.ejpb.2015.03.018_b2105","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.addr.2007.08.044","article-title":"Protein nanoparticles as drug carriers in clinical medicine","volume":"60","author":"Hawkins","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2015.03.018_b2110","doi-asserted-by":"crossref","first-page":"5474","DOI":"10.1158\/1078-0432.CCR-12-3110","article-title":"Weekly nab-Rapamycin in patients with advanced nonhematologic malignancies: final results of a phase I trial","volume":"19","author":"Gonzalez-Angulo","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejpb.2015.03.018_b2115","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1021\/mp900015y","article-title":"The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic","volume":"6","author":"Davis","year":"2009","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2015.03.018_b2120","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/nature08956","article-title":"Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles","volume":"464","author":"Davis","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.ejpb.2015.03.018_b2125","doi-asserted-by":"crossref","first-page":"5715","DOI":"10.1073\/pnas.0701458104","article-title":"Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA","volume":"104","author":"Heidel","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejpb.2015.03.018_b2130","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1002\/bit.21668","article-title":"Impact of tumor-specific targeting and dosing schedule on tumor growth inhibition after intravenous administration of siRNA-containing nanoparticles","volume":"99","author":"Bartlett","year":"2008","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.ejpb.2015.03.018_b2135","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.3390\/cancers3032888","article-title":"Nanotechnology-based detection and targeted therapy in cancer: nano-bio paradigms and applications","volume":"3","author":"Mousa","year":"2011","journal-title":"Cancers"},{"key":"10.1016\/j.ejpb.2015.03.018_b2140","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jconrel.2003.08.005","article-title":"Drug delivery to resistant tumors: the potential of poly(alkyl cyanoacrylate) nanoparticles","volume":"93","author":"Vauthier","year":"2003","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2015.03.018_b2145","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1586\/17434440.1.1.115","article-title":"Nanoparticles of biodegradable polymers for new-concept chemotherapy","volume":"1","author":"Feng","year":"2004","journal-title":"Expert Rev. Med. Devices"},{"key":"10.1016\/j.ejpb.2015.03.018_b2150","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/263797a0","article-title":"Polymers for the sustained release of proteins and other macromolecules","volume":"263","author":"Langer","year":"1976","journal-title":"Nature"},{"key":"10.1016\/j.ejpb.2015.03.018_b2155","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/jps.2600681215","article-title":"Adsorption of antineoplastic drugs to polyalkylcyanoacrylate nanoparticles and their release in calf serum","volume":"68","author":"Couvreur","year":"1979","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2015.03.018_b2160","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0169-409X(02)00044-3","article-title":"Nanoparticles in cancer therapy and diagnosis","volume":"54","author":"Brigger","year":"2002","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2015.03.018_b2165","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.jhep.2004.12.035","article-title":"Increase of doxorubicin sensitivity by doxorubicin-loading into nanoparticles for hepatocellular carcinoma cells in vitro and in vivo","volume":"42","author":"Barraud","year":"2005","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ejpb.2015.03.018_b2170","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S0168-3659(01)00342-X","article-title":"Tumour targeted delivery of encapsulated dextran\u2013doxorubicin conjugate using chitosan nanoparticles as carrier","volume":"74","author":"Mitra","year":"2001","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2015.03.018_b2175","first-page":"225","article-title":"Efficacy of nanoparticles containing irinotecan prepared using poly(dl-lactic acid) and poly(ethylene glycol)-poly(propylene glycol)-poly(ethylene glycol) against M5076 tumour in the early liver metastatic stage","volume":"13","author":"Machida","year":"2003","journal-title":"STP Pharm. Sci."},{"key":"10.1016\/j.ejpb.2015.03.018_b2180","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0169-409X(02)00226-0","article-title":"PEGylated nanoparticles for biological and pharmaceutical applications","volume":"55","author":"Otsuka","year":"2003","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2015.03.018_b2185","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1126\/science.8128245","article-title":"Biodegradable long-circulating polymeric nanospheres","volume":"263","author":"Gref","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.ejpb.2015.03.018_b2190","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1021\/ar9800993","article-title":"Biomaterials in drug delivery and tissue engineering: one laboratory\u2019s experience","volume":"33","author":"Langer","year":"1999","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.ejpb.2015.03.018_b2195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0168-3659(00)00339-4","article-title":"Biodegradable polymeric nanoparticles as drug delivery devices","volume":"70","author":"Soppimath","year":"2001","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2015.03.018_b2200","series-title":"Filled Elastomers Drug Delivery Systems","first-page":"45","article-title":"Pharmaceutical polymeric controlled drug delivery systems","author":"Kumar","year":"2002"},{"key":"10.1016\/j.ejpb.2015.03.018_b2205","doi-asserted-by":"crossref","first-page":"4087","DOI":"10.1016\/S0009-2509(03)00234-3","article-title":"Chemotherapeutic engineering: application and further development of chemical engineering principles for chemotherapy of cancer and other diseases","volume":"58","author":"Feng","year":"2003","journal-title":"Chem. Eng. Sci."},{"key":"10.1016\/j.ejpb.2015.03.018_b2210","doi-asserted-by":"crossref","first-page":"775","DOI":"10.5732\/cjc.010.10075","article-title":"Recent progress in nanotechnology for cancer therapy","volume":"29","author":"Tang","year":"2010","journal-title":"Chin. J. Cancer"},{"key":"10.1016\/j.ejpb.2015.03.018_b2215","unstructured":"Web of Knowledge_Literature Search, Tomson Reuters."},{"key":"10.1016\/j.ejpb.2015.03.018_b2220","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.phrs.2010.03.005","article-title":"Targeting nanoparticles to cancer","volume":"62","author":"Wang","year":"2010","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejpb.2015.03.018_b2225","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jconrel.2007.12.014","article-title":"Antitumor efficacy of cisplatin-loaded glycol chitosan nanoparticles in tumor-bearing mice","volume":"127","author":"Kim","year":"2008","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2015.03.018_b2230","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ejpb.2008.09.011","article-title":"In vivo investigation of tolerance and antitumor activity of cisplatin-loaded PLGA-mPEG nanoparticles","volume":"71","author":"Mattheolabakis","year":"2009","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2015.03.018_b2235","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0168-3659(01)00530-2","article-title":"PLGA\u2013mPEG nanoparticles of cisplatin: in vitro nanoparticle degradation, in vitro drug release and in vivo drug residence in blood properties","volume":"79","author":"Avgoustakis","year":"2002","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2015.03.018_b2240","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpb.2006.12.017","article-title":"Anticancer activity of cisplatin-loaded PLGA-mPEG nanoparticles on LNCaP prostate cancer cells","volume":"67","author":"Gryparis","year":"2007","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2015.03.018_b2245","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ejpb.2009.10.005","article-title":"Pharmacodynamics of cisplatin-loaded PLGA nanoparticles administered to tumor-bearing mice","volume":"74","author":"Moreno","year":"2010","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2015.03.018_b2250","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ejpb.2011.01.008","article-title":"Cisplatin-loaded gelatin-poly(acrylic acid) nanoparticles: synthesis, antitumor efficiency in vivo and penetration in tumors","volume":"79","author":"Ding","year":"2011","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2015.03.018_b2255","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.nano.2009.02.002","article-title":"PEGylated PLGA nanoparticles for the improved delivery of doxorubicin","volume":"5","author":"Park","year":"2009","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"10.1016\/j.ejpb.2015.03.018_b2260","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ejpb.2009.09.003","article-title":"Drug delivery to the brain using surfactant-coated poly(lactide-co-glycolide) nanoparticles: influence of the formulation parameters","volume":"74","author":"Gelperina","year":"2010","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2015.03.018_b2265","doi-asserted-by":"crossref","first-page":"e19121","DOI":"10.1371\/journal.pone.0019121","article-title":"Efficient chemotherapy of rat glioblastoma using doxorubicin-loaded PLGA nanoparticles with different stabilizers","volume":"6","author":"Wohlfart","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ejpb.2015.03.018_b2270","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jconrel.2008.09.086","article-title":"Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation","volume":"133","author":"Danhier","year":"2009","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2015.03.018_b2275","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1007\/s11095-009-9889-z","article-title":"Cytotoxicity of paclitaxel incorporated in PLGA nanoparticles on hypoxic human tumor cells","volume":"26","author":"Jin","year":"2009","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2015.03.018_b2280","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.ejphar.2011.09.023","article-title":"Long circulating chitosan\/PEG blended PLGA nanoparticle for tumor drug delivery","volume":"670","author":"Parveen","year":"2011","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejpb.2015.03.018_b2285","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jconrel.2010.08.021","article-title":"Paclitaxel-loaded pluronic nanoparticles formed by a temperature-induced phase transition for cancer therapy","volume":"148","author":"Oh","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2015.03.018_b2290","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jconrel.2009.11.002","article-title":"Paclitaxel-loaded poly(N-vinylpyrrolidone)-b-poly(\u03b5-caprolactone) nanoparticles: preparation and antitumor activity in vivo","volume":"142","author":"Zhu","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2015.03.018_b2295","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.bcp.2009.09.003","article-title":"Design of curcumin-loaded PLGA nanoparticles formulation with enhanced cellular uptake, and increased bioactivity in vitro and superior bioavailability in vivo","volume":"79","author":"Anand","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejpb.2015.03.018_b2300","doi-asserted-by":"crossref","first-page":"6597","DOI":"10.1016\/j.biomaterials.2010.04.062","article-title":"The in vitro stability and in vivo pharmacokinetics of curcumin prepared as an aqueous nanoparticulate formulation","volume":"31","author":"Mohanty","year":"2010","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejpb.2015.03.018_b2305","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ijpharm.2010.08.033","article-title":"Synthesis and in vitro\/in vivo anti-cancer evaluation of curcumin-loaded chitosan\/poly(butyl cyanoacrylate) nanoparticles","volume":"400","author":"Duan","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2015.03.018_b2310","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.canlet.2009.02.018","article-title":"Indomethacin-loaded nanocapsules treatment reduces in vivo glioblastoma growth in a rat glioma model","volume":"281","author":"Bernardi","year":"2009","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejpb.2015.03.018_b2315","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.3748\/wjg.14.3554","article-title":"Preparation of chitosan-polyaspartic acid-5-fluorouracil nanoparticles and its anti-carcinoma effect on tumor growth in nude mice","volume":"14","author":"Zhang","year":"2008","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.ejpb.2015.03.018_b2320","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.mcna.2007.05.009","article-title":"Recent advances in basic and clinical nanomedicine","volume":"91","author":"Morrow","year":"2007","journal-title":"Med. Clin. North Am."},{"key":"10.1016\/j.ejpb.2015.03.018_b2325","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1016\/j.biomaterials.2007.12.038","article-title":"Self-assembled glycol chitosan nanoparticles for the sustained and prolonged delivery of antiangiogenic small peptide drugs in cancer therapy","volume":"29","author":"Kim","year":"2008","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejpb.2015.03.018_b2330","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.2147\/IJN.S14753","article-title":"Endostar-loaded PEG-PLGA nanoparticles: in vitro and in vivo evaluation","volume":"5","author":"Hu","year":"2010","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.ejpb.2015.03.018_b2335","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.nano.2009.03.002","article-title":"Design and development of ligand-appended polysaccharidic nanoparticles for the delivery of oxaliplatin in colorectal cancer","volume":"6","author":"Jain","year":"2010","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"10.1016\/j.ejpb.2015.03.018_b2340","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ejps.2009.02.019","article-title":"Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer","volume":"37","author":"Shaikh","year":"2009","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2015.03.018_b2345","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1007\/s11095-008-9763-4","article-title":"Design of biodegradable nanoparticles for oral delivery of doxorubicin: in vivo pharmacokinetics and toxicity studies in rats","volume":"26","author":"Kalaria","year":"2009","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2015.03.018_b2350","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1007\/s11095-009-9965-4","article-title":"PLGA nanoparticles stabilized with cationic surfactant: safety studies and application in oral delivery of paclitaxel to treat chemical-induced breast cancer in rat","volume":"26","author":"Bhardwaj","year":"2009","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2015.03.018_b2355","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1002\/jps.22113","article-title":"Enhanced oral bioavailability of paclitaxel formulated in vitamin E-TPGS emulsified nanoparticles of biodegradable polymers: in vitro and in vivo studies","volume":"99","author":"Zhao","year":"2010","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2015.03.018_b2360","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jconrel.2010.03.012","article-title":"Increased oral bioavailability of paclitaxel by its encapsulation through complex formation with cyclodextrins in poly(anhydride) nanoparticles","volume":"145","author":"Ag\u00fceros","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2015.03.018_b2365","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.ejpb.2012.04.001","article-title":"Oral administration of paclitaxel with pegylated poly(anhydride) nanoparticles: permeability and pharmacokinetic study","volume":"81","author":"Zabaleta","year":"2012","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2015.03.018_b2370","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1016\/j.biomaterials.2009.02.045","article-title":"Poly(lactide)\u2013vitamin E derivative\/montmorillonite nanoparticle formulations for the oral delivery of docetaxel","volume":"30","author":"Feng","year":"2009","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejpb.2015.03.018_b2375","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.biomaterials.2010.09.037","article-title":"The effect of the oral administration of polymeric nanoparticles on the efficacy and toxicity of tamoxifen","volume":"32","author":"Jain","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejpb.2015.03.018_b2380","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jconrel.2006.10.032","article-title":"Effect of radiotherapy and hyperthermia on the tumor accumulation of HPMA copolymer-based drug delivery systems","volume":"117","author":"Lammers","year":"2007","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2015.03.018_b2385","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.nantod.2010.05.001","article-title":"Polymeric nanomedicines for image-guided drug delivery and tumor-targeted combination therapy","volume":"5","author":"Lammers","year":"2010","journal-title":"Nano Today"},{"key":"10.1016\/j.ejpb.2015.03.018_b2390","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1021\/nn900215k","article-title":"Multifunctional nanoparticles for combined doxorubicin and photothermal treatments","volume":"3","author":"Park","year":"2009","journal-title":"ACS Nano"},{"key":"10.1016\/j.ejpb.2015.03.018_b2395","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ejps.2012.12.006","article-title":"A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics","volume":"48","author":"Steichen","year":"2013","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2015.03.018_b2400","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/ijc.20405","article-title":"Efficacy of transferrin-conjugated paclitaxel-loaded nanoparticles in a murine model of prostate cancer","volume":"112","author":"Sahoo","year":"2004","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejpb.2015.03.018_b2405","doi-asserted-by":"crossref","first-page":"6184","DOI":"10.1021\/nn200739q","article-title":"A folate receptor-targeting nanoparticle minimizes drug resistance in a human cancer model","volume":"5","author":"Wang","year":"2011","journal-title":"ACS Nano"},{"key":"10.1016\/j.ejpb.2015.03.018_b2410","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1758-5996-3-11","article-title":"Albumin binding ligands and albumin conjugate uptake by cancer cells","volume":"3","author":"Frei","year":"2011","journal-title":"Diabetol. Metab. Syndr."},{"key":"10.1016\/j.ejpb.2015.03.018_b2415","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1097\/CAD.0b013e32830f9046","article-title":"Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status","volume":"19","author":"Desai","year":"2008","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.ejpb.2015.03.018_b2420","doi-asserted-by":"crossref","unstructured":"O. D\u2019Cruz, M. Piacente, V. Trieu, C. Tao, N. Desai, ABI-013: a novel nanoparticle albumin-bound (nab) docetaxel analog with superior antitumor activity over docetaxel, in: AACR 101st Annual Meeting 2010, Cancer Research, American Association for Cancer Research, Washington, DC, 2010.","DOI":"10.1158\/1538-7445.AM10-4420"},{"key":"10.1016\/j.ejpb.2015.03.018_b2425","doi-asserted-by":"crossref","unstructured":"O. D\u2019Cruz, M. Piacente, V. Trieu, C. Tao, N. Desai, Cardiovascular and CNS safety profile of ABI-013, a novel nanoparticle albumin-bound (nab) analog of docetaxel in: AACR 101st Annual Meeting 2010, Cancer Research, American Association for Cancer Research, Washington, DC, 2010.","DOI":"10.1158\/1538-7445.AM10-2617"},{"key":"10.1016\/j.ejpb.2015.03.018_b2430","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1002\/jps.22298","article-title":"Preparation and characterization of Apo2L\/TNF-related apoptosis-inducing ligand\u2013loaded human serum albumin nanoparticles with improved stability and tumor distribution","volume":"100","author":"Kim","year":"2011","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2015.03.018_b2435","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.colsurfb.2011.10.029","article-title":"Hyaluronic acid-based nanocarriers for intracellular targeting: interfacial interactions with proteins in cancer","volume":"99","author":"Choi","year":"2012","journal-title":"Colloids Surf., B"},{"key":"10.1016\/j.ejpb.2015.03.018_b2440","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.biomaterials.2009.09.030","article-title":"Self-assembled hyaluronic acid nanoparticles for active tumor targeting","volume":"31","author":"Choi","year":"2010","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejpb.2015.03.018_b2445","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1016\/j.biomaterials.2010.11.010","article-title":"PEGylation of hyaluronic acid nanoparticles improves tumor targetability in vivo","volume":"32","author":"Choi","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejpb.2015.03.018_b2450","doi-asserted-by":"crossref","first-page":"8591","DOI":"10.1021\/nn202070n","article-title":"Smart nanocarrier based on PEGylated hyaluronic acid for cancer therapy","volume":"5","author":"Choi","year":"2011","journal-title":"ACS Nano"},{"key":"10.1016\/j.ejpb.2015.03.018_b2455","doi-asserted-by":"crossref","first-page":"7181","DOI":"10.1016\/j.biomaterials.2011.06.028","article-title":"Self-assembled nanoparticles based on hyaluronic acid-ceramide (HA-CE) andPluronic\u00ae for tumor-targeted delivery of docetaxel","volume":"32","author":"Cho","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejpb.2015.03.018_b2460","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0928-0987(02)00257-9","article-title":"Self-assembled nanoparticles of hydrophobically-modified polysaccharide bearing vitamin H as a targeted anti-cancer drug delivery system","volume":"18","author":"Na","year":"2003","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2015.03.018_b2465","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1166\/jbn.2011.1340","article-title":"Targeted delivery of methotrexate to tumor cells using biotin functionalized methotrexate-human serum albumin conjugated nanoparticles","volume":"7","author":"Taheri","year":"2011","journal-title":"J. Biomed. Nanotechnol."},{"key":"10.1016\/j.ejpb.2015.03.018_b2470","first-page":"1863","article-title":"Use of biotin targeted methotrexate-human serum albumin conjugated nanoparticles to enhance methotrexate antitumor efficacy","volume":"6","author":"Taheri","year":"2011","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.ejpb.2015.03.018_b2475","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0169-409X(99)00062-9","article-title":"Targeted drug delivery via the folate receptor","volume":"41","author":"Sudimack","year":"2000","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2015.03.018_b2480","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1002\/jps.20457","article-title":"Folate receptor-mediated drug targeting: from therapeutics to diagnostics","volume":"94","author":"Hilgenbrink","year":"2005","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2015.03.018_b2485","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.urolonc.2007.03.015","article-title":"Nanoparticles for drug delivery in cancer treatment","volume":"26","author":"Haley","year":"2008","journal-title":"Urol. Oncol.: Semin. Orig. Invest."},{"key":"10.1016\/j.ejpb.2015.03.018_b2490","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.biomaterials.2008.09.056","article-title":"Single-step surface functionalization of polymeric nanoparticles for targeted drug delivery","volume":"30","author":"Patil","year":"2009","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejpb.2015.03.018_b2495","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s12645-010-0006-0","article-title":"Evaluation of cytotoxicity and mechanism of apoptosis of doxorubicin using folate-decorated chitosan nanoparticles for targeted delivery to retinoblastoma","volume":"1","author":"Parveen","year":"2010","journal-title":"Cancer Nano"},{"key":"10.1016\/j.ejpb.2015.03.018_b2500","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ejpb.2010.05.005","article-title":"Folate-mediated poly(3-hydroxybutyrate-co-3-hydroxyoctanoate) nanoparticles for targeting drug delivery","volume":"76","author":"Zhang","year":"2010","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2015.03.018_b2505","doi-asserted-by":"crossref","first-page":"5417","DOI":"10.1016\/j.biomaterials.2011.04.006","article-title":"Folate-decorated nanogels for targeted therapy of ovarian cancer","volume":"32","author":"Nukolova","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejpb.2015.03.018_b2510","doi-asserted-by":"crossref","first-page":"4057","DOI":"10.1016\/j.bmc.2011.05.016","article-title":"Improved therapeutic effect of folate-decorated PLGA\u2013PEG nanoparticles for endometrial carcinoma","volume":"19","author":"Liang","year":"2011","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejpb.2015.03.018_b2515","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ijpharm.2010.12.022","article-title":"Characterization, blood profile and biodistribution properties of surface modified PLGA nanoparticles of SN-38","volume":"406","author":"Ebrahimnejad","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2015.03.018_b2520","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S1357-2725(99)00070-9","article-title":"The transferrin receptor: role in health and disease","volume":"31","author":"Ponka","year":"1999","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.ejpb.2015.03.018_b2525","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.addr.2003.07.004","article-title":"Mechanisms of TfR-mediated transcytosis and sorting in epithelial cells and applications toward drug delivery","volume":"55","author":"Widera","year":"2003","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2015.03.018_b2530","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/med.10008","article-title":"Transferrin\/transferrin receptor-mediated drug delivery","volume":"22","author":"Li","year":"2002","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejpb.2015.03.018_b2535","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jconrel.2009.08.024","article-title":"Novel anti-tumor strategy: PEG-hydroxycamptothecin conjugate loaded transferrin-PEG-nanoparticles","volume":"141","author":"Hong","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2015.03.018_b2540","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1080\/10611860410001701706","article-title":"Validation of the transferrin receptor for drug targeting to brain capillary endothelial cells in vitro","volume":"12","author":"Visser","year":"2004","journal-title":"J. Drug Target."},{"key":"10.1016\/j.ejpb.2015.03.018_b2545","doi-asserted-by":"crossref","first-page":"7748","DOI":"10.1016\/j.biomaterials.2010.06.053","article-title":"Transferrin-conjugated nanoparticles of poly(lactide)-d-\u03b1-tocopheryl polyethylene glycol succinate diblock copolymer for targeted drug delivery across the blood\u2013brain barrier","volume":"31","author":"Gan","year":"2010","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejpb.2015.03.018_b2550","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3109\/02652048.2010.522257","article-title":"Transferrin-appended PEGylated nanoparticles for temozolomide delivery to brain: in vitro characterisation","volume":"28","author":"Jain","year":"2011","journal-title":"J. Microencapsul."},{"key":"10.1016\/j.ejpb.2015.03.018_b2555","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S1748-0132(07)70083-X","article-title":"Targeted nanoparticles for cancer therapy","volume":"2","author":"Gu","year":"2007","journal-title":"Nano Today"},{"key":"10.1016\/j.ejpb.2015.03.018_b2560","doi-asserted-by":"crossref","first-page":"17356","DOI":"10.1073\/pnas.0809154105","article-title":"Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles","volume":"105","author":"Dhar","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejpb.2015.03.018_b2565","doi-asserted-by":"crossref","first-page":"7668","DOI":"10.1158\/0008-5472.CAN-04-2550","article-title":"Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells","volume":"64","author":"Farokhzad","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejpb.2015.03.018_b2570","doi-asserted-by":"crossref","first-page":"8010","DOI":"10.1016\/j.biomaterials.2011.07.004","article-title":"Aptamer-functionalized PEG\u2013PLGA nanoparticles for enhanced anti-glioma drug delivery","volume":"32","author":"Guo","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejpb.2015.03.018_b2575","doi-asserted-by":"crossref","first-page":"5737","DOI":"10.1016\/j.biomaterials.2009.07.008","article-title":"Targeted epidermal growth factor receptor nanoparticle bioconjugates for breast cancer therapy","volume":"30","author":"Acharya","year":"2009","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejpb.2015.03.018_b2580","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1126\/science.2470152","article-title":"Studies of the HER-2\/neu proto-oncogene in human breast and ovarian cancer","volume":"244","author":"Slamon","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.ejpb.2015.03.018_b2585","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.canlet.2005.01.041","article-title":"Herceptin: mechanisms of action and resistance","volume":"232","author":"Nahta","year":"2006","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejpb.2015.03.018_b2590","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.ejps.2009.07.006","article-title":"Nanomedicines for active targeting: physico-chemical characterization of paclitaxel-loaded anti-HER2 immunonanoparticles and in vitro functional studies on target cells","volume":"38","author":"Cirstoiu-Hapca","year":"2009","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2015.03.018_b2595","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.jconrel.2010.02.026","article-title":"Benefit of anti-HER2-coated paclitaxel-loaded immuno-nanoparticles in the treatment of disseminated ovarian cancer: therapeutic efficacy and biodistribution in mice","volume":"144","author":"Cirstoiu-Hapca","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2015.03.018_b2600","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ejps.2012.06.016","article-title":"Trastuzumab decorated methotrexate\u2013human serum albumin conjugated nanoparticles for targeted delivery to HER2 positive tumor cells","volume":"47","author":"Taheri","year":"2012","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2015.03.018_b2605","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jconrel.2008.03.010","article-title":"Preparation and characterization of PE38KDEL-loaded anti-HER2 nanoparticles for targeted cancer therapy","volume":"128","author":"Chen","year":"2008","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2015.03.018_b2610","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ijpharm.2009.04.037","article-title":"Inactivation of harmful tumour-associated proteolysis by nanoparticulate system","volume":"381","author":"Kos","year":"2009","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2015.03.018_b2615","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/0092-8674(94)90007-8","article-title":"Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels","volume":"79","author":"Brooks","year":"1994","journal-title":"Cell"},{"key":"10.1016\/j.ejpb.2015.03.018_b2620","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.addr.2008.08.005","article-title":"Active targeting schemes for nanoparticle systems in cancer therapeutics","volume":"60","author":"Byrne","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2015.03.018_b2625","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1007\/s11095-009-9837-y","article-title":"Design of a multifunctional PLGA nanoparticulate drug delivery system: evaluation of its physicochemical properties and anticancer activity to malignant cancer cells","volume":"26","author":"Wang","year":"2009","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2015.03.018_b2630","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jconrel.2009.08.011","article-title":"Targeting of tumor endothelium by RGD-grafted PLGA-nanoparticles loaded with paclitaxel","volume":"140","author":"Danhier","year":"2009","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2015.03.018_b2635","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1016\/j.biomaterials.2011.02.044","article-title":"Angiopep-conjugated poly(ethylene glycol)-co-poly(\u03b5-caprolactone) nanoparticles as dual-targeting drug delivery system for brain glioma","volume":"32","author":"Xin","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejpb.2015.03.018_b2640","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1023\/A:1011007014510","article-title":"Binding and internalization of an LFA-1-derived cyclic peptide by ICAM receptors on activated lymphocyte: a potential ligand for drug targeting to ICAM-1-expressing cells","volume":"18","author":"Yusuf-Makagiansar","year":"2001","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2015.03.018_b2645","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ejps.2009.02.008","article-title":"ICAM-1 targeting of doxorubicin-loaded PLGA nanoparticles to lung epithelial cells","volume":"37","author":"Chittasupho","year":"2009","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2015.03.018_b2650","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.addr.2007.06.003","article-title":"Biodegradable nanoparticles for cytosolic delivery of therapeutics","volume":"59","author":"Vasir","year":"2007","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2015.03.018_b2655","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ejps.2009.11.010","article-title":"Intracellular trafficking of nuclear localization signal conjugated nanoparticles for cancer therapy","volume":"39","author":"Misra","year":"2010","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2015.03.018_b2660","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.drup.2005.10.002","article-title":"RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature","volume":"8","author":"Temming","year":"2005","journal-title":"Drug Resist. Updates"},{"key":"10.1016\/j.ejpb.2015.03.018_b2665","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1097\/CAD.0b013e3282a213ce","article-title":"Binding and internalization of NGR-peptide-targeted liposomal doxorubicin (TVT-DOX) in CD13-expressing cells and its antitumor effects","volume":"18","author":"Garde","year":"2007","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.ejpb.2015.03.018_b2670","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.ccr.2009.10.013","article-title":"Tissue-penetrating delivery of compounds and nanoparticles into tumors","volume":"16","author":"Sugahara","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejpb.2015.03.018_b2675","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1517\/17425247.2011.585155","article-title":"Antiangiogenic anticancer strategy based on nanoparticulate systems","volume":"8","author":"Yoncheva","year":"2011","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ejpb.2015.03.018_b2680","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.nano.2008.07.007","article-title":"Targeting of albumin-embedded paclitaxel nanoparticles to tumors","volume":"5","author":"Karmali","year":"2009","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"10.1016\/j.ejpb.2015.03.018_b2685","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1083\/jcb.200304132","article-title":"Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels","volume":"163","author":"Christian","year":"2003","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.ejpb.2015.03.018_b2690","doi-asserted-by":"crossref","first-page":"8674","DOI":"10.1158\/0008-5472.CAN-10-1917","article-title":"F3-targeted cisplatin-hydrogel nanoparticles as an effective therapeutic that targets both murine and human ovarian tumor endothelial cells in vivo","volume":"70","author":"Winer","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejpb.2015.03.018_b2695","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1371\/journal.pone.0024075","article-title":"Therapeutic efficacy and safety of paclitaxel\/lonidamine loaded EGFR-targeted nanoparticles for the treatment of multi-drug resistant cancer","volume":"6","author":"Milane","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ejpb.2015.03.018_b2700","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/nrg2006","article-title":"Strategies for silencing human disease using RNA interference","volume":"8","author":"Kim","year":"2007","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.ejpb.2015.03.018_b2705","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/nature07758","article-title":"The promises and pitfalls of RNA-interference-based therapeutics","volume":"457","author":"Castanotto","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.ejpb.2015.03.018_b2710","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1773-2247(12)50004-3","article-title":"Polymeric micelles for siRNA delivery","volume":"22","author":"Falamarzian","year":"2012","journal-title":"J. Drug Del. Sci. Tech."},{"key":"10.1016\/j.ejpb.2015.03.018_b2715","doi-asserted-by":"crossref","first-page":"5174","DOI":"10.1021\/nn300942b","article-title":"Targeted polymeric micelles for siRNA treatment of experimental cancer by intravenous injection","volume":"6","author":"Christie","year":"2012","journal-title":"ACS Nano"},{"key":"10.1016\/j.ejpb.2015.03.018_b2720","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ijpharm.2013.02.050","article-title":"Amphiphilic polyallylamine based polymeric micelles for siRNA delivery to the gastrointestinal tract: in vitro investigations","volume":"447","author":"Guo","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2015.03.018_b2725","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/ppsc.201200061","article-title":"Polymeric-micelle-based nanomedicine for siRNA delivery","volume":"30","author":"Liu","year":"2013","journal-title":"Part. Part. Syst. Charact."},{"key":"10.1016\/j.ejpb.2015.03.018_b2730","series-title":"RNA Interference from Biology to Therapeutics","first-page":"161","article-title":"Polymeric micelles for siRNA delivery","author":"Pittella","year":"2013"},{"key":"10.1016\/j.ejpb.2015.03.018_b2735","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0014-5793(03)01505-9","article-title":"Conjugate for efficient delivery of short interfering RNA (siRNA) into mammalian cells","volume":"558","author":"Muratovska","year":"2004","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ejpb.2015.03.018_b2740","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1021\/mp9000124","article-title":"Synthesis and biological evaluation of a bioresponsive and endosomolytic siRNA\u2212polymer conjugate","volume":"6","author":"Meyer","year":"2009","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2015.03.018_b2745","first-page":"10","article-title":"Defined folate-PEG-siRNA conjugates for receptor-specific gene silencing","volume":"31","author":"Dohmen","year":"2012","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ejpb.2015.03.018_b2750","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1002\/marc.201000804","article-title":"Conjugation of siRNA with comb-type PEG enhances serum stability and gene silencing efficiency","volume":"32","author":"Gunasekaran","year":"2011","journal-title":"Macromol. Rapid Commun."},{"key":"10.1016\/j.ejpb.2015.03.018_b2755","first-page":"676","article-title":"Preparation and characterization of polymeric nanoparticles for siRNA delivery to down-regulate the expressions of exogenous and endogenous target genes","volume":"67","author":"Huang","year":"2012","journal-title":"Pharmazie"},{"key":"10.1016\/j.ejpb.2015.03.018_b2760","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2147\/IJN.S8503","article-title":"The investigation of polymer-siRNA nanoparticle for gene therapy of gastric cancer in vitro","volume":"5","author":"Wu","year":"2010","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.ejpb.2015.03.018_b2765","series-title":"RNA Therapeutics","first-page":"53","article-title":"Progress in siRNA delivery using multifunctional nanoparticles","author":"Gao","year":"2010"},{"key":"10.1016\/j.ejpb.2015.03.018_b2770","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1007\/s11095-012-0961-8","article-title":"Ternary polymeric nanoparticles for oral siRNA delivery","volume":"30","author":"Zhang","year":"2013","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2015.03.018_b2775","doi-asserted-by":"crossref","first-page":"7596","DOI":"10.1021\/ja300690j","article-title":"Pendant polymer:amino-\u03b2-cyclodextrin:siRNA guest: host nanoparticles as efficient vectors for gene silencing","volume":"134","author":"Kulkarni","year":"2012","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejpb.2015.03.018_b2780","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/584060","article-title":"BSA nanoparticles for siRNA delivery: coating effects on nanoparticle properties, plasma protein adsorption, and in vitro siRNA delivery","author":"Yogasundaram","year":"2012","journal-title":"Int. J. Biomater."},{"key":"10.1016\/j.ejpb.2015.03.018_b2785","doi-asserted-by":"crossref","first-page":"7203","DOI":"10.1002\/anie.201201390","article-title":"Tumor-homing poly-siRNA\/glycol chitosan self-cross-linked nanoparticles for systemic siRNA delivery in cancer treatment","volume":"51","author":"Lee","year":"2012","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejpb.2015.03.018_b2790","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jconrel.2011.07.035","article-title":"Systemic delivery of siRNA with cationic lipid assisted PEG-PLA nanoparticles for cancer therapy","volume":"156","author":"Yang","year":"2011","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2015.03.018_b2795","doi-asserted-by":"crossref","first-page":"594","DOI":"10.4161\/cbt.8.7.7790","article-title":"RNA interference of MBD1 in BxPC-3 human pancreatic cancer cells delivered by PLGA-poloxamer nanoparticles","volume":"8","author":"Luo","year":"2009","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.ejpb.2015.03.018_b2800","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1177\/1947601911418499","article-title":"The roles of the methyl-CpG binding proteins in cancer","volume":"2","author":"Parry","year":"2011","journal-title":"Genes Cancer"},{"key":"10.1016\/j.ejpb.2015.03.018_b2805","doi-asserted-by":"crossref","first-page":"5671","DOI":"10.1016\/j.biomaterials.2010.03.069","article-title":"Surface functionalisation of PLGA nanoparticles for gene silencing","volume":"31","author":"Andersen","year":"2010","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejpb.2015.03.018_b2810","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.biomaterials.2009.09.048","article-title":"The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance","volume":"31","author":"Patil","year":"2010","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejpb.2015.03.018_b2815","doi-asserted-by":"crossref","first-page":"3910","DOI":"10.1158\/1078-0432.CCR-10-0005","article-title":"Targeted gene silencing using RGD-labeled chitosan nanoparticles","volume":"16","author":"Han","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejpb.2015.03.018_b2820","unstructured":"Sirnaomics Inc."},{"key":"10.1016\/j.ejpb.2015.03.018_b2825","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s10059-011-0051-5","article-title":"Nanomaterials for cancer therapy and imaging","volume":"31","author":"Bae","year":"2011","journal-title":"Mol. Cells"},{"key":"10.1016\/j.ejpb.2015.03.018_b2830","doi-asserted-by":"crossref","first-page":"4174","DOI":"10.1002\/anie.200805998","article-title":"All-in-one target-cell-specific magnetic nanoparticles for simultaneous molecular imaging and siRNA delivery","volume":"48","author":"Lee","year":"2009","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejpb.2015.03.018_b2835","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.biomaterials.2010.09.039","article-title":"Surface functionalized hollow manganese oxide nanoparticles for cancer targeted siRNA delivery and magnetic resonance imaging","volume":"32","author":"Bae","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejpb.2015.03.018_b2840","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1517\/17425247.3.2.205","article-title":"Multi-functional polymeric nanoparticles for tumour-targeted drug delivery","volume":"3","author":"van Vlerken","year":"2006","journal-title":"Expert Opin. Drug Deliv."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641115001514?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641115001514?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T17:17:08Z","timestamp":1747847828000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641115001514"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":568,"alternative-id":["S0939641115001514"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2015.03.018","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2015.03.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}